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(57) ABSTRACT 
The various embodiments of the present disclosure relate 
generally to single molecule sensitive probes for detecting 
RNA, and more particularly to multivalent fluorescent probes 
for detecting a single molecule of RNA in a cell. The present 
invention includes a RNA imaging probe comprising: a mul-
tivalent core comprising a plurality of attachment sites; a 
plurality of RNA/DNA chimeric oligonucleotides having a 
specificity for a target RNA, wherein a RNA/DNA chimeric 
oligonucleotide is bound to an attachment site of the multi-
valent core; and a plurality of fluorophores, wherein a fluo-
rophore is bound to the RNA/DNA chimeric oligonucleotide. 
32 Claims, 15 Drawing Sheets 
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SINGLE MOLECULE SENSITIVE PROBES 
FOR DETECTING RNA 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims, under 35 U.S.C. §119, the benefit 
of International Patent Application Serial Number PCT/ 
US2010/028670, filed 25 Mar. 2010, which claims the benefit 
of U.S. Provisional Application Ser. No. 61/163,292, filed 25 
Mar. 2009, both of which are hereby incorporated by refer-
ence in their entirety as if fully set forth below. 
BACKGROUND OF THE INVENTION 
1. Technical Field 
The various embodiments of the present disclosure relate 
generally to single molecule sensitive probes for detecting 
RNA. More specifically, the various embodiments of the 
present disclosure are directed to multivalent fluorescent 
probes for detecting a single molecule of RNA in a living or 
fixed cell or tissue. 
2. Description of Related Art 
In recent years, the imaging of RNAs in live cells has 
garnered growing attention with a variety of interesting meth-
ods developed for this purpose. This research has been driven 
by the increased appreciation for the role of post-transcrip-
tional regulation on the function of RNA molecules, the role 
of genomic RNA in viral assembly, and the cellular stress 
response in pathogenesis. 
2 
lar beacon approach have the ability to study endogenous or 
non-engineered RNAs, but neither have achieved single mol-
ecule sensitivity with endogenous targets. 
When imaging endogenous RNA, the sensitivity of the 
probe is extremely important. First, mRNA is not highly 
abundant within cells, and second, RNA function is governed 
by the set ofhighly abundant proteins that interact with it. The 
difference in their concentrations makes studying these inter-
actions via imaging very difficult. Therefore, RNA probes 
10 must be sensitive enough to detect a small number ofRNAs 
within a sea of proteins. In order to achieve single molecule 
sensitivity, the above techniques require the binding of many 
probes; for example, binding sites for up to 50 MS2-GFP 
molecules or 96 molecular beacon molecules are necessary. 
15 Given both the additions to the RNA and the size of the 
probes, large molecular weight additions are required to 
achieve single molecule sensitivity. These additions could 
have effects on both RNA localization and dynamics. Further, 
for probe-based methods, delivery into the correct cellular 
20 compartment is critical in order for the pro bes to bind rapidly 
to their target. Delivery methods that result in accumulation 
of probe in the nucleus of cells or utilize endocytic vesicles 
can lead to nonspecific signal and degradation of the probe. 
In order to make an advance in the area of RNA imaging, 
25 new techniques must be capable of imaging endogenous 
RNA, have single molecule sensitivity, allow for the imaging 
of multiple RNAs, and minimize the number and molecular 
weight of probes binding to the RNA. It is to the provision of 
such RNA imaging techniques that the various embodiments 
30 of the present invention are directed. 
Various technologies and methodologies have been devel-
oped to study intracellular RNA biology in live cells includ-
ing: plasmid-based systems, where the fluorescent tag and/or 
the RNA to be tagged are expressed within the cell, or systems 
based on exogenous RNA-targeting fluorescent probes, 35 
which when introduced into the cell, bind to their target via 
Watson-Crick base pairing. Currently, expressing both the 
RNA and a fluorescent tag using a plasmid-based system is 
the state-of-the-art in this field. 
BRIEF SUMMARY OF THE INVENTION 
Various embodiments of the present invention are directed 
to single molecule sensitive probes for detecting RNA. More 
specifically, the various embodiments of the present disclo-
sure are directed to multivalent fluorescent probes for detect-
ing a single molecule of RNA in a living or fixed cell or tissue. 
An aspect of the present invention includes a biomolecule 
Three strategies using plasmid expressed probes have been 
demonstrated in mammalian cells: (1) a GFP-MS2 fusion 
protein probe, which binds to multiple binding sites encoded 
in an expressed target RNA; (2) GFP-RNA binding peptide 
fusion probes, which bind to a 15 nucleotide RNA hairpin 
encoded in the expressed target RNA; and (3) probes com-
posed of Pumilio homology domains (PUM-HD) fused to 
sections of split EGFP, which target two closely spaced 8 
nucleotide endogenous sequences. These systems have been 
used to study cytoplasmic, nuclear mRNA and mitochondrial 
RNA. A fourth technique, which is an extension of the first 
three, introduces an exogenous probe, a microinjection-de-
livered molecular beacon that targets multiple binding sites in 
an expressed target mRNA. 
Employing plasmid-derived probes and RNA give these 
methods tremendous flexibility but they have limitations. 
First, they can only be used in cell types that allow for efficient 
transfection. Second, plasmid-derived mRNA often lack 
intrans, both the correct number and position and the exact 
3'-untranslated region (UTR) sequence, which can strongly 
influence mRNA translational efficiency, decay, and stability. 
40 probe comprising: a multivalent core comprising a plurality 
of attachment sites; a ligand having specificity for a target, 
wherein the ligand is bound to an attachment site of the 
multivalent core; and a reporter molecule, wherein the 
reporter molecule is bound to the ligand. The ligand can 
45 comprise a plurality ofligands, and a ratio of the plurality of 
ligands to the plurality of attachment sites on the multivalent 
core can be equal to or less than about 1. The reporter mol-
ecule can comprise a plurality of reporter molecules, and a 
ratio of reporter molecule to ligand is greater than or equal to 
50 about 1. The target can be one or more biomolecules, for 
example a RNA. 
In one embodiment of the present invention, the ligand can 
comprise a nucleic acid. The nucleic acid can comprises an 
attachment region, a spacer region, and a hybridization 
55 region. Within one or more ofany of these regions, the nucleic 
acid can include a moiety sufficient to bind a reporter mol-
ecule. In some embodiments, the reporter molecule can com-
prise a fluorophore. In an exemplary embodiment, the ratio of 
reporter molecule (e.g., fluorophore) to ligand is equal to 
60 about 3. The multivalent core can be made of many materials, 
such as avidin or a derivative thereof or a multivalent poly-
ethylene glycol core. In various embodiments of the present 
invention, the biomolecule probe can further comprise a tar-
In the case of viral RNA, additions to viral genomes affect 
replication efficiency, assembly, and viral egress. In addition, 
plasmid-derived RNAs are often overexpressed, changing the 
fundamental stoichiometry underlying the RNAs expression. 
Therefore, it is advantageous to target endogenous RNA in 65 
order to improve RNA biology studies. Of the techniques 
mentioned above, only the PUM-HD fusions and the molecu-
geting moiety, an epitope moiety, or a combination thereof. 
Another aspect of the present invention includes a RNA 
imaging probe comprising: a multivalent core comprising a 
plurality of attachment sites; a plurality of RNA/DNA chi-
US 8,785,615 B2 
3 
meric oligonucleotides having a specificity for a target RNA, 
wherein a RNA/DNA chimeric oligonucleotide is bound to an 
attachment site of the multivalent core; and a plurality of 
fluorophores, wherein a fluorophore is bound to the RNA/ 
DNA chimeric oligonucleotide. The ratio of fluorophore to 5 
RNA/DNA chimeric oligonucleotide can be greater than 1. In 
an exemplary embodiment of the present invention, the ratio 
of fluorophore to RNA/DNA chimeric oligonucleotide is 
greater than or equal to about 3. The RNA/DNA chimeric 
oligonucleotide can comprise an attachment region, a spacer 10 
region, and a hybridization region. The multivalent core can 
comprise a tetravalent strepavidin core, and the attachment 
region of the RNA/DNA chimeric oligonucleotide can com-
prise biotin. Alternatively, the multivalent core can comprise 15 
a multivalent polyethylene glycol core, and the attachment 
group can comprise a 5' thiol modified 2'-0-methyl uridine. 
The spacer region can comprise a plurality of deoxythy-
midines, a plurality of deoxyadenonsines, or combinations 
thereof. In an exemplary embodiment, the RNA/DNA chi- 20 
meric oligonucleotide further comprises a plurality of amino-
modified deoxythymidines. The RNA imaging probe of the 
present invention can further comprise a targeting moiety, an 
epitope moiety, or a combination thereof. 
Another aspect of the present invention includes a method 25 
for detecting a single molecule of RNA using a RNA imaging 
probe comprising: delivering an effective amount of the RNA 
imaging probe to a cell; and detecting a molecule of a target 
RNA in a cell. The effective amount of an RNA imaging 
probe has a concentration of less than about 1 micromolar 30 
(µM), and preferably a concentration ranging from about 5 
nanomolar (nM) to about 30 nanomolar (nM). The delivering 
an effective amount of an RNA imaging probe to a cell can 
comprise permeabilizing the cell with streptolysin 0 or 35 
microinj ecting the RNA imaging pro be into a cell. The detect-
ing a molecule of a RNA in a cell can comprise visualizing the 
association of the RNA imaging probe with the molecule of a 
target RNA in a cell through microscopy. The target RNA can 
be a native, non-engineered RNA, such as for example a 40 
cellular RNA or a viral RNA. The methods of the present 
invention can further comprise detecting a protein that is 
associated with the target RNA. 
Other aspects and features of embodiments of the present 
invention will become apparent to those of ordinary skill in 45 
the art, upon reviewing the following description of specific, 
exemplary embodiments of the present invention in conjunc-
tion with the accompanying figures. 
BRIEF DESCRIPTION OF DRAWINGS 50 
4 
FIG. le provides an intensity profile ofwidefield (gradual 
curve) and deconvolved images (distinct peaks) in the line of 
the merge image of FIG. ld. 
FIG. 2a illustrates ~-actin mRNA and a 'scrambled' probe 
imaged with a laser scarming confocal microscope where all 
image planes are represented. 
FIG. 2b provides intensity profiles along the line in FIG. 
2a. The box highlights the large numbers of ~-actin mRNA 
individual granules at the cell periphery detected by the tar-
geted probe, but not by the scrambled probe. 
FIG. 2c illustrates a single optical plane of the same cell as 
in FIG. 2a resulting from widefield-deconvolution imaging. 
Scale bar, 5 µm. 
FIG. 2d illustrates a single optical plane of two livingA549 
cells (nucleus denoted with dashed line) imaged at 1 Hz for 3 
mM and 5 Hz for 30 s, respectively. Inset, images of boxed 
regions, including traces of ~-actin mRNA granule trajecto-
ries for70 s (1 Hz) and30 s (5 Hz). Starting points are denoted 
by arrows. Scale bars, 10 µm (3 µmin insets). 
FIG. 3a shows fluorescence images of a live A549 cell 
imaged 24 h after infection and 48 h after transfection, show-
ing no stress granules. Scale bar, 10 mm. 
FIG. 3b is a live-cell image of a single optical plane of 
GFP-TIA-1 and Cy3B labeled hRSV-targeted MTRIPs (25 
nM) in anA549 cell, 24 h after infection, 48 h after transfec-
tion and 20 mM after exposure to 1 mM sodium arsenite. 
Arrowheads denote stress granules. Scale bar, 10 µm. 
FIG. 3c illustrates time-lapse images of stress granule 
(green) collision, penetration, and separation of a viral RNA 
granule (red).All times are given in seconds. Scale bars, 1 µm. 
FIG. 3dprovides images of the docking ofa stress granule 
and viral RNA granule, which occurred for only 45 s before 
separation. All granule interactions shown were imaged in the 
area denoted by the box in FIG. 3b. All times are given in 
seconds. Scale bars, 1 µm. 
FIG. 4a illustrates images of single Cy3B and Atta 647N 
probes, respectively, at 2 nM. Inset depicts image of a mixture 
ofCy3B andAtto 647N MTRIPs demonstrating probe inde-
pendence. 
FIG. 4b depicts unimodal histograms of the mean intensity 
within each diffraction-limited spot constructed from 750-
1000 detected probes. 
FIG. 4c provides three-dimensional intensity profiles of 
representative probes post-deconvolution, which further 
demonstrate that single probes were imaged. 
FIG. Sa illustrates MTRIPs using human ~-actin probe 1 
(red, left panel), delivered at 30 nM, colocalize (yellow, right 
panel) with ZBPl (green, center panel), especially in the ends 
of pseudopods. 
FIG. Sb is an intensity profile drawn through one of the 
pseudopods, which further demonstrates colocalization. 
FIG. la is a schematic of a multiply labeled tetravalent 
RNA imaging probe (MTRIPs), where fluorophores 
(spheres) are conjugated to amino-modified chimera oligo-
nucleotides (helices) and bound to streptavidin. 
FIG. lb is a schematic of cells, permeabilized with strep-
tolysin 0, where probes were allowed to diffuse through 
pores followed by rapid binding of the probes to targets, 
which was visualized after light stimulation. 
FIG. Sc illustrates the colocalization of ~-actin mRNA 
with F-actin. MTRIPs (red, left panel) delivered at 1 nM show 
colocalization (purple, right panel) with phalloidin stained 
55 stress fibers (blue, center panel). Inset image within merge 
focuses on a region of significant co localization. 
FIG. le demonstrates that single RNAs bound to multiple 60 
probes were recognized by the enhanced signal-to-back-
ground ratio. 
FIG. Sd demonstrates an intensity profile of FIG. Sc show-
ing the correlation of F-actin signal (blue) with MTRIPs 
(red). 
FIG. 6a illustrates quantification of 3D colocalization of 
single (human (~-actin mRNA probe 1) MTRIP targeted to 
~-actin mRNA and ZBPl in a motile epithelial cell. XY, XZ, 
and YZ profiles at location designated by the cross-hair are 
provided as evidence of co localization within both a pseudo-
FIG. ld illustrates live-cell widefield, deconvolved, and 
merged images of a single optical plane of Cy3B-labeled 
hRSV-targeted probes in a noninfectedA549 cell. Scale bars, 
10 µm (2.5 µmin inset, which is a magnification of the boxed 
region). 
65 pod (YZ) and within the perinuclear region (XZ). 
FIG. 6b is a scatter plot ofvoxel intensities generated from 
the 3D reconstruction of voxels and the Manders overlap 
US 8,785,615 B2 
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coefficient calculated. In this case, the Manders overlap coef-
ficient was 0.92, suggesting significant co localization in three 
dimensions. 
FIG. 7a is an extended view ofarp2 (red) and ~-actin (blue) 
mRNA, and ZBPI (green) in a motile primary chicken 5 
embryonic fibroblasts CEF. Scale bar represents 5 µm. 
FIG. 7b are intensity profiles through two cross-sections 
(denoted I and 2) of the extended view reveal two types of 
localization; within the perinuclear region, ~-actin mRNA 
signal is not correlated with the arp2 mRNA signal, especially 10 
from approximately pixel I 00 to 225 in profile I and from I 00 
to 150 and 175 to 225 in profile 2; ZBPI and ~-actinmRNA 
are correlated within these same regions. 
FIGS. 7c:fillustrate a single plane image of the cell, near 15 
the glass surface and within a lamellipodium (indicated by the 
white box). Co localization of arp2 (red, far left panel) mRNA, 
~-actin (blue, central left panel) mRNA, and ZBPI (green, 
central right panel) can be observed especially within the 
lamellipodium near the leading edge. Scale bar represents 5 20 
µm. 
FIGS. 7g-h is a live cell image and intensity profile, respec-
tively, of arp2 (red, left panel) and ~-actin (blue, central 
panel) mRNA tagged with the same MTRIPs as above; gran-
ules within a protrusion of CEF show significant colocaliza- 25 
tion. The dashed white region represents the cell nucleus. 
Scale bar represents 5 µm. 
FIG. 7i provides phase contrast images of primary CEFs 
before and after SLO exposure, which shows no significant 
changes in cellular morphology. The images were taken 20 30 
minutes after streptolysin 0 (SLO) exposure. Scale bar rep-
resents 50 µm. 
6 
FIG. 14a is a schematic of an 8-arm PEG conjugated to 
fluorescently labeled oligonucleotides and TAT peptide 
(heavy blue line). 
FIG. 14b is a schematic of cells, reversibly permeabilized 
with streptolysin 0. Probes diffused into the cytoplasm, 
bound to target RNA, and were visualized under a fluores-
cence microscope. 
FIG. 14c is a schematic of transduction of a TAT-PEG 
probe without streptolysin 0 permeabilization. 
FIG. 14d demonstrates that detection of RNA is achieved 
through the increased signal intensity when multiple probes 
are bound to a single RNA. 
FIG.15a illustrates thatAtto 488 (green), Cy3B (red), and 
Atta 647N (blue) labeled probes were adsorbed onto glass 
and analyzed for the colocalization and aggregation. Scale 
bar is 2 µm. 
FIGS. lSb-d depict corresponding intensity histograms of 
FIG. 15a showing a unimodal distribution consistent with 
single probes. 
FIGS. 16a:f demonstrate distribution of PEG probes tar-
geted against hRSV in A549 cells and colocalization with 
endosomal marker CD63 and lysosomal marker LAMPI. (a) 
Probe (red) was delivered by SLO permeabilization, and (b) 
probe (red) was delivered by TAT conjugation. Extended 
focus of uninfected cells with probe (red) delivered by TAT 
conjugation and ( c) stained for CD63 (green) and ( d) LAMPI 
(green). Insets in c and d show single plane from boxed 
region. Extended focus of hRSV infected cells with probe 
(red) delivered by TAT conjugation and stained for ( e) CD63 
(green) and (f) LAMPI (green). Scale bars are 10 µm. 
FIGS. 17 a-b demonstrate distribution of probes (red) into 
fixedhRSV (a) infected and (b) noninfected cells and staining 
for the viral protein N (green) and DAPI (blue). Scale bar, I 0 
µm. 
FIG. 17c demonstrates magnification of boxed region in 
FIG. 17a. Scale bar, 5 µm. 
FIG. 17d is an intensity profile along line in FIG. 17c. 
FIGS. 17e:fillustrate the distribution of probes (red) into 
live hRSV (e) infected and (f) noninfected cells. Scale bar, 10 
FIG. Sa-b illustrate that MTRIPs targeted the viral 
genomic RNA of hRSV (red, right panel) and colocalized 35 (yellow, left panel) with hRSV nucleocapsid protein (green, 
center panel) in infected cells. DAPI staining stains the 
nucleus of the cell. Co localization was observed in the images 
and quantified in intensity profiles (b) along the line as 
denoted by the white arrow. 40 µm. 
FIGS. Sc-d demonstrate that little background was 
observed in non-infected cells. Colocalization was observed 
in the images and quantified in intensity profiles along the line 
as denoted by the white arrow. 
FIGS. 9a-b illustrate quantification of3D co localization of 45 
MTRIP targeted to hRSV genomic RNA (red) and nucleo-
capsid protein (green) in an epithelial cell. (a) XY, XZ, and YZ 
profiles at location designated by the cross-hair are provided 
as evidence of co localization. Strong yellow signal represent-
ing colocalization can be observed in both cross-sections. (b) 50 
From the 3D reconstruction of voxels, a scatter plot of voxel 
intensities was generated, and the Manders overlap coeffi-
cient calculated. In this case the Manders overlap coefficient 
was 0.65, demonstrating colocalization in three dimensions. 
FIGS. lOa-b provide a comparison of tetravalent MTRIPs 55 
and noncovalent probes (single multiply-labeled ligand) both 
targeted to hRSV genomic RNA (red). FIG. lOa provides 
representative images from infections targeted by each probe 
type. FIG. lOb demonstrates that RNA granules from over 30 
cells for both the tetravalent and monovalent probes were 60 
counted via Volocity using the same conditions. 
FIG. 11 illustrates time-lapse imaging of granule fusion. 
FIGS. l8a-b illustrates the distribution of probes (red) into 
fixedhRSV (a) infected and (b) noninfected cells and staining 
for the viral protein N (green) and DAPI (blue). Scale bar, I 0 
µm. 
FIG. 18c illustrates magnification of boxed region in FIG. 
l8a. Scale bar, 5 µm. 
FIG. l8d is an intensity profile along line in FIG. 18c. 
FIGS. 18e:f demonstrate the distribution of probes (red) 
into live hRSV (e) infected and (f) noninfected cells. Scale 
bar, 10 µm. 
FIGS. l9a-d illustrate the absorbance spectra of labeled 
probes (a) Cy3b-labelled oligonucleotides, (b) Cy3b-labelled 
oligonucleotides in the PEG probes, ( c) Cy3b-labelled oligo-
nucleotides in the PEG-TAT probes, and (d) unlabelled oli-
gonucleotides in the PEG-TAT-FAM probes. 
FIG. 20 is an ethidium bromide stained 15% TBE-UREA 
gel of the probes, where lane I is a low range ssRNA ladder; 
lane 2 is unconjugated oligonucleotides; lane 3 is PEG probe, 
and lane 4 is PEG-TAT probe. 
DETAILED DESCRIPTION OF THE INVENTION 
Scale bar, I µm. 
FIG. 12 illustrates time-lapse imaging of granule splitting. 
Scale bar, I µm. 
FIG. 13 illustrates a live-dead assay assessment of the 
effects of SLO on A549 cells. 
The present invention may be understood more readily by 
reference to the following Detailed Description of the inven-
65 tion and the Examples included therein. Before the present 
compounds, compositions, and methods are disclosed and 
described, it is to be understood that this invention is not 
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limited to any specific probes, specific targets, specific 
nucleic acid probes, specific nucleic acid targets, specific cell 
types, specific conditions, or specific methods, etc., as such 
may, of course, vary, and the numerous modifications and 
variations therein will be apparent to those skilled in the art. 
Throughout this description, various components can be 
identified as having specific values or parameters, however, 
these items are provided as exemplary embodiments. Indeed, 
the exemplary embodiments do not limit the various aspects 
and concepts of the present invention as many comparable 
parameters, sizes, ranges, and/or values can be implemented. 
The terms "first," "second," and the like, "primary," "second-
ary," and the like, do not denote any order, quantity, or impor-
tance, but rather are used to distinguish one element from 
another. Further, the terms "a," "an," and "the" do not denote 
a limitation of quantity, but rather denote the presence of "at 
least one" of the referenced item. Thus, for example, refer-
ence to "a nucleic acid probe" can mean that one or more than 
one nucleic acid probe can be utilized. 
An aspect of the present invention includes a biomolecule 
probe comprising: a multivalent core comprising a plurality 
of attachment sites; a ligand having specificity for a target, 
wherein the ligand is bound to an attachment site of the 
multivalent core; and a reporter molecule, wherein the 
reporter molecule is bound to the ligand. 
As used herein, the term "biomolecule" refers to many 
organic molecules that can be produced by a living organism 
or synthesized, including, but not limited to, proteins, pep-
tides, polysaccharides, oligosaccharides, glycoproteins, lip-
ids, phospholipids, polynucleotides, oligonucleotides, as 
well as small molecules such as primary metabolites, second-
ary metabolites, and other biological molecules that is 
capable of activating inhibiting or modulating a biochemical 
pathway or process. 
The term "ligand" as used herein refers to a biomolecule or 
other chemical entity having a capacity or affinity for binding 
to a target. A ligand can include a protein or portion thereof, 
a peptide, a polysaccharide, an oligosaccharide, a sugar, a 
glycoprotein, a lipid, a phospholipid, a polynucleotide or 
portion thereof, an oligonucleotide, an aptamer, a nucleotide, 
a nucleoside, DNA, RNA, a DNA/RNA chimera, an antibody 
8 
molecules that is capable of activating inhibiting or modulat-
ing a biochemical pathway or process, and/or any other affin-
ity agent, among others. 
The ligand may be, for example, one member of a bioint-
eractive complex that comprises two or more biomolecules 
that have a binding affinity for one another. Consequently, the 
target may also be one member of such a biointeractive com-
plex that demonstrates binding affinity for the ligand. 
Examples of biointeractive complexes (e.g., ligand-target 
10 complexes) can include for example, a protein:protein com-
plex, a protein:peptide complex, a polynucleotide:polynucle-
otide complex, a polynucleotide:oligonucleotide complex, an 
oligonucleotide:protein complex, a peptide:polynucleotide 
complex, an antibody: antigen complex, an enzyme: substrate 
15 complex, or a biomolecule: drug complex, among others. 
The phrase "having specificity for a target" with respect of 
the ligand as used herein can also be referred to as the "bind-
ing activity" or "binding affinity" of the ligand relative to the 
target. These phrases may be used interchangeably herein and 
20 are meant to refer to the tendency of a ligand to bind or not to 
bind to a target. The energetics of these interactions are sig-
nificant in "binding activity" and "binding affinity" because 
they define the necessary concentrations of interacting bio-
molecules, the rates at which these biomolecules are capable 
25 of associating, and the relative concentrations of bound and 
free biomolecules in a solution. The energetics are character-
ized through, among other ways, the determination of a dis-
sociation constant, Kd. The specificity of the binding is 
defined in terms of the comparative dissociation constants 
30 (Kd) of the ligand for target as compared to the dissociation 
constant with respect to the ligand and other materials in the 
cellular environment or unrelated molecules in general. Typi-
cally, the Kd for the ligand with respect to the target will be 
2-fold, preferably 5-fold, more preferably 10-fold less than 
35 Kd with respect to target and the unrelated material or accom-
panying material in the cellular environment. Even more pref-
erably, the Kd will be 50-fold less, more preferably 100-fold 
less, and more preferably 200-fold less than Kd with respect to 
target and the unrelated material or accompanying material in 
40 the cellular environment. 
or fragment thereof, a nucleic acid-protein fusion, a hapten, a 
nucleic acid, and a virus or a portion thereof, as well as small 45 
molecules (e.g., a chemical compound) such as primary 
metabolites, secondary metabolites, and other biological 
molecules that is capable of activating inhibiting or modulat-
ing a biochemical pathway or process, and/or any other affin-
In the various embodiments of the present invention, the 
ligand is bound to a multivalent core comprising a plurality of 
attachment points. As used herein, the term "plurality" refers 
to more than one. As a result, a multivalent core comprises 
more than one attachment sites that have the capacity to bind 
a ligand. The core can be made of many materials, including, 
but not limited to poly( ethylene )glycol and derivatives 
thereof or avidin and derivatives thereof. 
For example, a core comprising poly(ethylene)glycol can 
have a molecular weight ranging from about 5 kilodaltons to 
about 50 kilodaltons. More preferably, the poly(ethylene) 
glycol can have a molecular weight ranging from about 5 
kilodaltons to about 30 kilodaltons, and even more preferably 
about 20 kilodaltons. The poly(ethylene)glycol can be a 
multi-arm poly( ethylene )glycol, having two arms, four arms, 
six arms, or eight arms. Each arm represents an attachment 
site on the multivalent core. 
ity agent, among others. A ligand can come from many 50 
sources, including libraries, such as the aptamer libraries, 
phage display libraries, or any other library as would be 
apparent to one of ordinary skill in the art after review of the 
disclosure of the present invention presented herein. 
As used herein, a "target" or "target molecule" refers to a 55 
biomolecule that could be the focus of a therapeutic drug 
strategy or diagnostic assay or a combination thereof, some-
times referred to as a theranostic. Therefore, a target can 
include, without limitation, a protein or portion thereof, a 
peptide, a polysaccharide, an oligosaccharide, a sugar, a gly- 60 
coprotein, a lipid, a phospholipid, a polynucleotide or portion 
thereof, an oligonucleotide, an aptamer, a nucleotide, a 
nucleoside, DNA, RNA, a DNA/RNA chimera, an antibody 
or fragment thereof, a nucleic acid-protein fusion, a hapten, a 
nucleic acid, and a virus or a portion thereof, as well as small 65 
molecules (e.g., a chemical compound) such as primary 
metabolites, secondary metabolites, and other biological 
In another example, a core can comprise avidin or a deriva-
tive thereof, such as streptavidin, NeutrAvidin and CaptAvi-
din, among others. Avidin or derivatives thereof demonstrate 
a strong affinity for biotin and are generally capable of bind-
ing four biotins per molecule (i.e., tetravalent). 
Regardless of the type of cores, in some embodiments of 
the present invention, all of the attachment sites of the mul-
tivalent core are bound to a ligand. In such embodiments, the 
ratio of ligand to attachment sites on the multivalent core is 
equal to about 1. In other embodiments of the present inven-
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tion, only a portion of the attaclnnent sites of the multivalent 
core are bound to a ligand or a ligand may be bound to 
multiple attaclnnent sites. Consequently, ratio of ligands to 
attaclnnent sites may be less than about 1. Further, on a given 
multivalent core, one or more types ofligand may be bound to 
the multivalent core. 
In the various embodiments of the present invention, the 
ligand is also bound to a reporter molecule. As used herein, a 
"reporter molecule" is a detectable compound or composition 
that is conjugated directly or indirectly to another molecule 
(such as the ligand or multivalent core) to facilitate detection 
of that molecule. Specific, non-limiting examples ofreporter 
molecules include fluorescent and fluorogenic moieties, 
enzymatic moieties, haptens, affinity tags, and radioactive 
isotopes. The reporter molecule can be directly detectable 
(e.g., optically detectable) or indirectly detectable (for 
example, via interaction with one or more additional mol-
ecules that are in turn detectable). A ligand may be labeled 
with one or more reporter molecules. Thus, the ratio of 
reporter molecules to ligands may be greater than or equal to 
about 1. 
Exemplary reporter molecules in the context of the probes 
disclosed herein are fluorophores. Numerous fluorochromes 
are known to those of skill in the art, and can be selected, for 
example from Invitrogen, e.g., see, The Handbook-A Guide 
to Fluorescent Probes and Labeling Technologies, Invitrogen 
Detection Technologies, Molecular Probes, Eugene, Oreg.). 
Examples of particular fluorophores that can be attached (for 
example, chemically conjugated) to a FPC nucleic acid mol-
ecule are provided in U.S. Pat. No. 5,866,366 to Nazarenko et 
al., such as 4-acetamido-4'-isothiocyanatostilbene-2,2' disul-
fonic acid, acridine and derivatives such as acridine and acri-
dine isothiocyanate, 5-(2'-aminoethyl)aminonaphthalene-l-
sulfonic acid (EDANS), 4-amino-N-[3-vinylsulfonyl) 
phenyl]naphthalimide-3,5 disulfonate (Lucifer Yellow VS), 
N-(4-anilino-l-naphthyl)maleimide, anthranilamide, ATTO 
dyes, Brilliant Yellow, coumarin and derivatives such as cou-
marin, 7-amino-4-methylcoumarin (AMC, Coumarin 120), 
7-amino-4-trifluoromethylcouluarin (Coumaran 151); cya-
nines; cyanosine; 4',6-diaminidino-2-phenylindole (DAPI); 
5',5"-dibromopyrogallol-sulfonephthalein (Bromopyro-
gallol Red); 7-diethyl amino-3-( 4'-isothiocyanatophenyl)-4-
methylcoumarin; diethylenetriamine pentaacetate; 4,4'-di-
isothiocyanatodihydro-stilbene-2,2'-disulfonic acid; 4,4'-
diisothiocyanatostilbene-2,2'-disulfonic acid; 
5-[ dimethylamino ]naphthalene-1-sulfonyl chloride (DNS, 
dansyl chloride); 4-( 4'-dimethylaminophenylazo )benzoic 
acid (DABCYL); 4-dimethylaminophenylazophenyl-4'-
isothiocyanate (DABITC); eosin and derivatives such as 
eosin and eosin isothiocyanate; erythrosin and derivatives 
such as erythrosin Band erythrosin isothiocyanate; ethidium; 
fluorescein and derivatives such as 5-carboxyfluorescein 
(FAM), 5-( 4,6-dichlorotriazin-2-yl)aminofluorescein 
(DTAF), 2'7'-dimethoxy-4'5'-dichloro-6-carboxyfluorescein 
(JOE), fluorescein, fluorescein isothiocyanate (FITC), and 
QFITC(XRITC); IR dyes, 2',7'-difluorofluorescein (OR-
EGON GREEN); fluorescamine; IR144; IR1446; Malachite 
Green isothiocyanate; 4-methylumbelliferone; ortho cresol-
phthalein; nitrotyrosine; pararosaniline; Phenol Red; B-phy-
coerythrin; o-phthaldialdehyde; pyrene and derivatives such 
as pyrene, pyrene butyrate and succinimidy 1 1-pyrene 
butyrate; Reactive Red 4 (Cibacro Brilliant Red 3B-A); 
rhodamine and derivatives such as 6-carboxy-X-rhodamine 
(ROX), 6-carboxyrhodamine (R6G), lissamine rhodamine B 
sulfonyl chloride, rhodamine (Rhod), rhodamine B, 
rhodamine 123, rhodamine X isothiocyanate, rhodamine 
green, sulforhodamine B, sulforhodamine 101 and sulfonyl 
10 
chloride derivative of sulforhodamine 101 (Texas Red); N,N, 
N' ,N'-tetramethy 1-6-carboxyrhodamine (TAMRA); tetram-
ethy l rhodamine; tetramethyl rhodamine isothiocyanate 
(TRITC); riboflavin; rosolic acid and terbium chelate deriva-
tives as well as other photostable dyes known in the art. 
An exemplary embodiment of the present invention 
includes a ribonucleic acid (RNA) imaging probe. As the 
name implies, the probe can be utilized to visualize the pres-
ence of various types of RNA in cell, including, but not 
10 limited to messenger RNA (mRNA), transfer RNA (tRNA), 
ribosomal RNA (rRNA), transfer-messenger RNA (tmRNA), 
microRNA (miRNA), small interfering RNA (siRNA), small 
nuclear RNA (snRNA), small nucleolar RNA (snoRNA), and 
viral genomes comprising RNA and RNA-based intermedi-
15 ates thereof, among others. 
In an exemplary embodiment, the RNA imaging probe 
includes an oligonucleotide as the ligand. As used herein, an 
"oligonucleotide" refers to a plurality of nucleic acids having 
a sequence sufficient to hybridize to at least a portion of a 
20 target nucleic acid, such as a target RNA. As used herein, the 
term "nucleic acid" is intended to include DNA molecules 
(e.g., cDNA or genomic DNA) and RNA molecules, as 
described above, and analogs of the DNA or RNA generated 
using nucleotide analogs. As referred to herein, nucleic acids 
25 that are "complementary" can be perfectly or imperfectly 
complementary, as long as the desired property resulting from 
the complementarity is not lost, e.g., ability to hybridize to the 
target nucleic acid. 
The oligonucleotide sequence can demonstrate substantial 
30 complementarity to the target nucleic acid sequence. As used 
herein, the term "substantial complementarity" to the target 
nucleic acid sequence means that a oligonucleotide includes 
a sequence that has at least 51 %, 52%, 53%, 54%, 55%, 56%, 
57%, 58%, 59%, 60%, 61 %, 62%, 63%, 64%, 65%, 66%, 
35 67%, 68%, or 69%, 70%, 71 %, 72%, 73%, 74%, 75%, 76%, 
77%, 78%, or 79%, preferably at least 80%, 81 %, 82%, 83%, 
84%, 85%, 86%, 87%, 88%, or 89%, more preferably at least 
90%, 91 %, 92%, 93%, or 94%, and most preferably at least 
95%, 96%, 97%, 98%, 99%, or 100% sequence complemen-
40 tarity to the target nucleic acid sequence. 
The nucleic acids of the present invention may be substan-
tially isolated or alternatively unpurified. An "isolated" or 
"purified" nucleic acid is one that is substantially separated 
from other nucleic acid molecules that are present in the 
45 source of the nucleic acid. Preferably, an "isolated" nucleic 
acid is substantially free of sequences that naturally flank the 
nucleic acid (i.e., sequences located at the 5' and 3' ends of the 
nucleic acid). Moreover, an "isolated" nucleic acid molecule 
can be substantially free of other cellular material, or culture 
50 medium when produced by recombinant techniques, or 
chemical precursors or other chemicals when chemically syn-
thesized. The oligonucleotide ligand typically comprises sub-
stantially purified nucleic acid. 
The nucleic acid probes of the invention can be DNA, RNA 
55 or a chimeric mixture of DNA and RNA, or derivatives or 
modified versions of DNA or RNA, so long as the oligonucle-
otide is capable of hybridizing to the desired target nucleic 
acid. For example, an oligonucleotide probe of the present 
invention can be chemically synthesized using naturally 
60 occurring nucleotides or variously modified nucleotides 
designed to increase the biological stability of the molecules 
or to increase the physical stability of the duplex formed 
between the complimentary nucleic acids (i.e., the ligand and 
target). A preferred example of a class of modified nucle-
65 otides which can be used to generate the nucleic acid probes 
is a 2'-0-methyl nucleotide. Additional examples of modified 
nucleotides which can be used to generate the nucleic acid 
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probes include, but are not limited to, 5' thiol modified 2'-0-
methyl uridine, 5-fluorouracil, 5-bromouracil, 5-chlorou-
racil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 
5-( carboxyhydroxy lmethy I) uracil, 5-carboxymethylami-
nomethy 1-2-thiouridine, 5-carboxymethylaminomethy !u-
racil, dihydrouracil, beta-D-galactosylqueosine, inosine, 
N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 
2,2-dimethy !guanine, 2-methy !adenine, 2-methy !guanine, 
3-methylcytosine, 5-methylcytosine, N6-adenine, 7-meth-
y !guanine, 5-methy laminomethy !uracil, 5-methoxyaminom-
ethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxy-
carboxymethy !uracil, 5-methoxyuracil, 2-methy lthio-N 6-
isopenteny ladenine, uracil-5-oxyacetic acid (v), 
wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-me-
thyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, 
uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid 
(v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypro-
pyl) uracil, (acp3), 2,6-diaminopurine, and locked nucleic 
acids. 
The oligonucleotide comprises three regions: a hybridiza-
tion region, a spacer region, and an attachment region. In an 
exemplary embodiment, the oligonucleotide comprises, in a 
5' to 3' direction, an attachment region, a spacer region, and a 
hybridization region. 
The hybridization region of the oligonucleotide probe typi-
cally comprises a region of nucleotide sequence that hybrid-
izes to at least about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 
18, 19,20,21,22,23,24,25,26,27,28,29,30,35,40,450r 
50 consecutive nucleotides of a target nucleic acid. In an 
exemplary embodiment, the hybridization region comprises 
about 10 to about 20 2'-0-Methyl nucleotides, wherein the 
hybridization region has an average G/C content of about 
50%. The hybridization region can have complementarity to 
any target RNA of interest, for example a cellular RNA asso-
ciated with a biochemical or signaling pathway, a cellular 
RNA associated with specific disease or condition, a viral 
RNA, a bacterial RNA, a RNA associated with an inherited 
disease, or a RNA associated with cancer, among others. 
The spacer region of the oligonucleotide operates to spa-
tially separate the hybridization region from the multivalent 
core. Although not wishing to be bound by any particular 
theory, the hybridization efficiency of the RNA imaging 
probe can be increased by spacing away the hybridization 
region from the surface of the multivalent core making the 
hybridization region more accessible for hybridization with 
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appropriate nucleotide derivative and number thereof to con-
jugate different reporter molecules of fluorophores and to 
tune the sensitivity of the probe, respectively. 
Selection of an attachment region for the oligonucleotide 
depends largely upon the type of multivalent core to which the 
oligonucleotide will be attached. For example, in the context 
of an avidin-based core, the attachment region can comprise 
a 5' biotin modification to the oligonucleotide. Alternatively, 
in the context of a poly(ethylene)glycol-based core, the 
10 attachment region can comprise a 5' thiol modified 2'-0-
methyl uridine residue. 
In addition to the ligands (e.g., oligonucleotides) described 
above, the probes of the present invention can further com-
prise a targeting moiety or an epitope moiety. As used herein, 
15 the term "targeting moiety" refers to a substance associated 
with the multivalent core that enhances binding, transport, 
accumulation, residence time, bioavailability, or modifies 
biological activity of the probe. The targeting moiety can 
include, but is not limited to, an organic or inorganic mol-
20 ecule, a peptide, a peptide mimetic, a protein, an antibody or 
fragment thereof, a growth factor, an enzyme, a lectin, an 
antigen or immunogen, a virus or component thereof, a recep-
tor, a receptor ligand, a toxin, a polynucleotide, an oligo-
nucleotide or aptamer, a nucleotide, a carbohydrate, a sugar, 
25 a lipid, a glycolipid, a nucleoprotein, a glycoprotein, a lipo-
protein, a steroid, a hormone, a chemoattractant, a cytokine, a 
chemokine, or a drug, among others. 
The term epitope moiety, as used herein, refers to any 
structure, sequence, or antigenic determinant that is recog-
30 nized by an antibody. Examples of suitable epitope moieties 
include, but are not limited to, a FLAG-tag, a HA tag, a c-myc 
tag, a polyhistidine tag, green fluorescent protein (GFP), 
digoxigenin, an a-tubulin tag, a B-tag, an E tag, a herpes 
simplex virus gD tag, a Pk-tag, a protein C tag, a T7 tag, a 
35 vesicular stomatitis virus glycoprotein tag, biotin, or a glu-
tathione-S-transferase tag. 
Another aspect of the present invention comprises a 
method for detecting a single molecule of RNA using the 
RNA imaging probe described above. Such a method com-
40 prises delivering an effective amount of an RNA imaging 
probe to a cell and detecting a molecule of a RNA in a cell. As 
used herein, the term "cell" refers to all eukaryotic and 
prokaryotic cells, as well as unicellular organism and multi-
cellular organisms or cells or tissues derived therefrom. 
45 Indeed, the word cell can encompass both living cells and 
fixed cells. its target. The sequence and length of the spacer region can be 
determined empirically; however, it has been found that a 
spacer region having a sequence comprising a plurality of 
thymine bases, adenine bases, or combinations thereof pro-
vide sufficient spacing. Experimental data indicates that thy- 50 
mi dines, adenosines, or combinations thereof are particularly 
effective spacer regions. In an exemplary embodiment, the 
spacer regions comprises about 5 to about 10 nucleotides, and 
more preferably about 6 to about 7 nucleotides. 
The delivery of the probe can be accomplished by many 
methods known in the art. Although not wishing to be bound 
by any particular theory, it is currently believed that the deliv-
ery of probes to a cell should generally avoid the endocytic 
pathway, so as to avoid the accumulation of probes in endo-
somal compartments. The probes of the present invention can 
be delivered to cells through transfection methods; however, 
transfection is a generally inefficient process. Thus, preferred 
methods of delivery of the probe to a cell include microinjec-
tion, TAT-mediated transduction, or reversible cell permeabi-
lization, such as through the use of streptolysin 0. 
The phrase "effective amount" as used herein is an amount 
of a probe that produces a desired effect in a cell, such as 
The hybridization region and the spacer region can also 55 
comprise nucleotide derivatives suitable for conjugation of a 
reporter molecule. In an exemplary embodiment, the oligo-
nucleotide can contain about 2 to about 8 nucleotide deriva-
tives suitable for conjugation to a reporter molecule, and 
preferably about 3 to about 4 nucleotide derivatives. Such 
nucleotides may be located only in the hybridization region, 
only in the spacer region, or in both the hybridization region 
and the spacer region. In one example, amine-modified thy-
midines can be located in both the hybridization and spacer 
regions for conjugation of the oligonucleotide to NHS-ester 
fluorophores, such as Atta 488, Cy3B, or Atta 647N. Of 
course, one of ordinary skill in the art could determine the 
60 detecting a molecule of a RNA in a cell. This amount (i.e., 
dosage) may vary depending upon a number of factors, 
including, but not limited to, the characteristics of the probe 
(including activity, pharmacokinetics, pharmacodynamics, 
and bioavailability) and cell type, among others. One skilled 
65 in the art will be able to determine an effective amount 
through routine experimentation, namely by monitoring the 
cellular response to administration of a probe and adjusting 
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the dosage accordingly. Typically, fluorescent probes, such as 
molecular beacons, require relatively high doses to detect 
RNA, such as 1 µM to 2 µM. One particular advantage of the 
probes of the present invention is that these probes can be 
delivered at relatively low concentrations (less than 1 µM) 
and can detect single molecules of RNA. The probes of the 
present invention can be delivered in nanomolar concentra-
tions, such as about 1 nM to about 100 nM, and more prefer-
ably between about 5 nM to about 30 nM. 
Detecting a molecule of a RNA in a cell can involve many 10 
mechanisms of detection of nucleic acids know in the art. In 
an exemplary embodiment, detection of a molecule of RNA 
includes visualizing the association of the RNA imaging 
probe with the molecule of a RNA in a cell through many 
modes of microscopy, for example confocal microscopy or 15 
epifluorescent microscopy. Through the use of the probes and 
microscopy, it is possible to visualize and monitor the traf-
ficking of a target RNA through a cell. Detection of a mol-
ecule of RNA can also be performed by affinity chromatog-
raphy, such as through immunoprecipitation. By using 20 
affinity chromatography methods, such as immunoprecipita-
tion and the like, not only can the target RNA molecule be 
detected, but additional biomolecules (e.g., RNA, proteins, 
etc.) that are associated with the target RNA can also be 
detected and/or identified. Thus, the compositions and meth- 25 
ods of the present invention provide a valuable tool for the 
identification of the interactome associated with a target 
RNA. 
14 
resort may be had to various other embodiments, modifica-
tions, and equivalents thereof which, after reading the 
description herein, may suggest themselves to those skilled in 
the art without departing from the spirit of the present inven-
tion or the scope of the appended claims. 
Example 1 
Single Molecule-Sensitive Probes for Imaging RNA 
in Live Cells 
The below Example was published in Nature Methods, Vol. 
6, No. 5, (May 2009). Consequently the referenced Figures 
can be viewed in color in this publication, which is hereby 
incorporated by reference. 
Materials and Methods. 
MTRIPs. 
The 2' 0-methyl RNA-DNA chimera nucleic acid ligands 
were synthesized by Biosearch Technologies, Inc. Each con-
tains a 5' biotin modification and multiple dT-C6-NH2, modi-
fications. The streptavidin used for the core was purchased 
from Pierce. Probes were assembled by first labeling the free 
amine groups on the ligands with eitherCy3B-NHS ester (GE 
Healthcare) or Atta 64 7N-NHS ester (Atta-Tee GmbH) using 
manufacturers' protocols. Free dye was removed using both 
Nanosep spin colunms (Pall Corp.) and illustra G-25 size-
exclusion colunms (GE Healthcare). The purified ligands 
were resuspended in lx phosphate-buffered saline (PBS; pH 
7.4) and mixed at a 10: 1 molar ratio with streptavidin for 1 h Another particular advantage of the probes of the present 
invention is that they can be used to monitor native, non-
engineered RNA in a cell. A "native, non-engineered RNA" is 
an RNA that is not introduced into a cell through a plasmid or 
30 at room temperature (18-22° C.). Free ligands were removed 
using 30 kDa Nanosep spin colurmis, and stored at 1 mM final 
concentration in lxPBS at 4° C. When multiple probes were 
used, each probe was completely assembled and filtered sepa-
rately, and then mixed with equimolar concentrations in 
an RNA that has a sequence that has non-native sequences or 
additional sequences not normally present in the RNA. 
Although plasmid expressed RNAs could be studied using the 
probes of the present invention, the expression of plasmid-
derived RNA is not preferable as they alter the biology of 
RNA expression, translational efficiency, decay, and stability. 
The probes of the present invention overcome the shortcom-
ings associated with plasmid-expressed RNAs and these 40 
probes can be used to detect endogenous cellular RNAs with 
single molecule sensitivity. The probes of the present inven-
tion can also be used to visualize exogenous RNA, such as 
that derived from various microorganisms, such as bacteria, 
viruses, and fungi. 
It should be understood, of course, that the foregoing 
relates only to exemplary embodiments of the present inven-
tion and that numerous modifications or alterations may be 
made therein without departing from the spirit and the scope 
35 streptolysin 0 and medium just before delivery into cells. 
Cells and Virus. 
A549 lung carcinoma cells (American Type Culture Col-
lection CCL-185) were grown in DMEM (Sigma Aldrich) 
with 10% fetal bovine serum (FBS; Hyclone) with 100 U 
m1- 1 of penicillin and 100 mg m1- 1 of streptomycin. Virus 
used was the A2 strain of hRSV (American Type Culture 
Collection VR-1544) at a titer of lxl06 50% tissue culture 
infectious dose (TCID50) ml- 1 . The titer was evaluated by 
serial dilution and immunostaining, 4 dafter infection. Infec-
45 tion data shown (FIG. 3 and FIGS. 8-10) was at day 1 after 
infection and with a multiplicity of infection of 5. All cells 
were infected at greater than 80% confluence, by removing 
the media, washing with 1 xPBS (without Ca2+ and Mg2 +) and 
of the invention as set forth in this disclosure. Therefore, 50 
while embodiments of this invention have been described in 
then adding virus to the cells for 30 mM at 371 C. After the 
30-mM incubation, complete medium was added. For the 
motile epithelial cell experiments, A549 cells were seeded at 
detail with particular reference to exemplary embodiments, 
those skilled in the art will understand that variations and 
modifications can be effected within the scope of the inven-
tion as defined in the appended claims. Accordingly, the scope 
of the various embodiments of the present invention should 
not be limited to the above discussed embodiments, and 
should only be defined by the following claims and all equiva-
lents. 
It should be noted that all patents, patent applications, and 
references included herein are specifically incorporated by 
reference in their entireties. 
5% confluence such that there were a substantial number of 
cells without contacts with other cells. For the motile fibro-
blast experiments, primary chicken embryonic fibroblasts 
55 (Charles River Laboratories) were grown in CEF growth 
medium (Charles River Laboratories), containing 5% FBS 
and seeded at 5% confluence. 
Probe Delivery. 
MTRIPs were delivered into A549 and CEF cells using a 
60 reversible permeabilization method with streptolysin 0 
(Sigma). Cells grown in complete medium were first washed 
with 1 xPBS and then incubated with a mixture of0.2 U m1- 1 
of streptolysin 0 and probe in an appropriate amount of The present invention is further illustrated by way of the 
examples contained herein, which are provided for clarity of 
understanding. The exemplary embodiments should not to be 65 
construed in any way as imposing limitations upon the scope 
thereof. On the contrary, it is to be clearly understood that 
complete growth medium for 10 mM at 37° C. The mixture of 
streptolysin 0, probe and medium was then removed and 
replaced with fresh, complete growth medium or Leibovitz' s 
L15 medium supplemented with 10% FBS. Live cells were 
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imaged typically 20 min immediately after delivery by epif-
luorescence microscopy. Using streptolysin 0-based deliv-
ery, probes were delivered into A549 and CEF cells with 
100% efficiency. 
Counting Granules and Statistical Analysis of RNA Gran- 5 
ule Populations. 
For data shown in FIG. 2 and FIG. 10, granules were 
identified and counted using Improvision' s Volocity software 
in three dimensions using either confocal images or from 
widefield fluorescence images, deconvolved using an itera- 10 
tive deconvolution algorithm in Volocity. For data shown in 
FIG. 2, granules were counted using deconvolved data and 
identified based on the s.d. of intensities; 4 s.d. above the 
mean was used to locate the granules in all cases because it 
avoided the detection of noise or objects substantially smaller 15 
than the point spread function. Because of this, no limit on 
minimum granule size was necessary when counting gran-
ules. In general, the cells deconvolved using the three-dimen-
sional interative algorithm in Volocity lacked considerable 
noise due to filtering in the algorithm. Notably, the s.d. in 20 
mean granule intensity for the granules in FIG. 2c and in the 
seruni-starvedcell (data not shown) were only 25% and21 %, 
respectively, reflecting the uniformity of the granules when 
measured in three dimensions. For data shown in FIG. 10, the 
number of granules was detected using the same criteria using 25 
confocal data from tetravalent MTRIPs and a monovalent 
ligand (ligands not connected by streptavidin) in approxi-
mately 30 cells each. The results were compared using the 
Wilcoxon-Mann-Whitney (WMW) test to determine whether 
the two samples came from the same population. WMW is a 30 
nonparametric test is traditionally used to test equality of 
locations in two populations, but in its general form this test is 
about the equality of distributions. The null hypothesis states 
that the distributions of the two samples coincide and the 
alternative is that the distributions differ. The P value for 35 
WMW test when comparing the number of granules detected 
by each probe was 0.8737, which means that the evidence for 
the null hypothesis is decisive; consequently, the distributions 
were assumed to be the same. 
16 
observed; an imaging plane containing both RNA granules 
and stress granules was chosen and time-lapse microscopy 
was initiated. Out-of-focus light was removed using Voloci-
ty's 2D deconvolution algorithm. 
Starvation Assay. 
A549 cells were serum-starved in DMEM with 100 U m1- 1 
of penicillin and 100 mg m1- 1 of streptomycin for 48 h. 
MTRIPs (human (~-actin mRNA probes 1 and 2) were deliv-
ered with streptolysin 0. Twenty minutes after delivery, the 
cells were fixed in 4% paraformaldehyde and stained with 
DAPI. The granules in a particular cell were then counted 
using the method described above. 
Immunostaining. 
Twenty to thirty minutes after probe delivery, cells were 
fixed in 4% paraformaldehyde in lxPBS for 10 mM at room 
temperature. After fixation, cells were permeabilized using 
0.2% Triton-X 100 for 5 mM at room temperature, washed in 
1 xPBS, blocked for 30 mM in 5% BSA (ultrapure ), washed in 
lxPBS, incubated with primary antibody for 30 mM at 37° 
C., washed 3x with 1 xPBS, incubated in secondary antibody 
labeled with Alexa 488 for 30 min at 37° C., washed 3x with 
lxPBS, labeled with DAPI for 5 min (in the RSV experi-
ments) and then mounted in PVA with Dabco. The mono-
clonal antibody for the hRSV nucleocapsid protein was from 
Abeam, and the polyclonal Ab for ZBPl from the Bassett 
laboratory. Polyclonal ZBPl antibodies were produced by 
immunizing guinea pigs with a synthetic peptide correspond-
ing to residues 162-175 (SEQ ID NO 1: CGPENGRRGGFG-
SRG; the first Cys is for conjugation) within a hinge region 
between two RRM and four KH domains of human ZBPl. 
This region is conserved completely among mouse, rat and 
human ZBPl proteins, but not Imp2 or Imp3 The ZBPl 
antibody does not recognize mouse Imp2 or Imp3 by western 
blotting (data not shown). F-actin was stained using Alexa 
488-labeled phalloidin (Invitrogen). 
Fluorescence Imaging. 
Immobilized Cy3B and Atta 647N probes on the glass 
Plasmids and Transfections. 
The pSRa-GFP-HA-TIA-1 plasmid was used to image 
stress granules in living cells. A549 cells plated in penicillin-
and streptomycin-free medium were transfected using 
Fu gene HD (Roche) at a ratio of Fu gene HD to DNA of2.5 ml 
mg-1. 
40 surface were imaged using a Zeiss Axiovert 200M micro-
scope with an X63, NA=l.4 Plan-Apochromat objective, 
using Chroma 49004 ET-Cy3 and 49006 ET-Cy5 filter sets, 
with 500-ms exposures. An EXPO excite 120 light source 
with a ND (neutral density) 1/4 0.4 ( 40% transmission) was 
Time-Lapse Fluorescence Microscopy. 
45 used for fluorescence excitation, and a Hamamatsu ORCA-
ER AG for taking digital images. Live-cell images of single 
probes withinA549 cells were taken with 350 ms exposures 
under the same illumination conditions. Z-dimension stacks 
Live-cell video microscopy was performed using cells 
grown in Bioptechs T4 plates with an objective heater. The 
cells were imaged in Leibovitz's L15 medium supplemented 
with 10% FBS. Images were taken with a Zeiss Axiovert 50 
200M microscope, with an X63, numerical aperture (NA) 
= 1.4 Plan-Apochromat objective and Hamamatsu 0 RCA-ER 
AG camera, using Chroma 49002 ET-GFP and 49004 ET-Cy3 
filter sets, controlled by Volocity software. For ~-actin mRNA 
granule dynamics, images were taken either at 1 or 5 Hz with 55 
90-ms exposures for 3 mM and 30 s, respectively. For the 
stress granule-RNA experiments, images of GFP-TIA-1 and 
the Cy3B-labeled MTRIPS were taken at 0.2 Hz (every 5 s), 
with exposure times of71and41 ms, respectively, for up to 8 
min. Stress granule-RNA time-lapse microscopy. A549 cells, 60 
transfected with the above plasmid for 24 h were then infected 
with hRSV as above. Twenty-four hours after infection, the 
MTRIPs were delivered at 25 nM final concentration, and the 
cells exposed to 1.0 mM sodium arsenite for 30 min. During 
the 30-min incubation, the cells were observed periodically 65 
using epifluorescence microscopy. After 15 mM of exposure, 
stress granules (marked by GFP-TIA-1 aggregates) were 
were taken in both cases, in 200-nm steps, and deconvolved 
using Volocity iterative deconvolution algorithm. Cells used 
in the human ~-actin mRNA scrambled probe experiments 
were fixed after live-cell hybridization and imaged similarly 
to the immobilized probes, but with 200-ms exposures and 
deconvolved in Volocity. Time-lapse live cell images were 
taken as discussed above, and were processed with Volocity' s 
2D or fast deconvolution algorithm. In the stress granule 
control experiments, live cell images were taken similarly to 
the single probe images but with 50-ms exposures. hRSV 
after delivery, fixed-cell control experiments were imaged 
with a ZeissLSM 510 Meta using an X63, NA=l.4, Plan-
Apochromat objective. All images were taken using multi-
track scanning for each fluorophore to prevent bleed-through. 
Z-dimension stacks were taken in 0.5-mm increments; the 
543 nm laser (Cy3B probe) was set at 25% power, the 488 nm 
laser (for N protein immunostaining) was set at 37%, and the 
pinholes were set to an airy unit of 1 (equal to airy disk). 
~-actin mRNA, actin-related protein 2 homolog mRNA and 
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ZBPl, in the chicken embryonic fibroblasts, were imaged 
under similar conditions to the human ~-actin mRNA experi-
ments. 
Image Analysis. 
Images were analyzed using Volocity software and NIH 
ImageJ. Volocity was used to deconvolve the widefield 
images (2D and full-iterative), reconstruct the images in three 
dimensions, identify individual probes based on intensity and 
measure the mean intensity within granules of all sizes. It was 
also used to perform the three-dimensional co-localization 
calculations of Manders coefficient. The Color Profiler tool in 
ImageJ was used to obtain profile data for the intensity plots 
from the merged images. 
Live-Dead Assay. 
18 
Fluorophores were chosen with quantum yields above 65% 
and they exhibited little triplet state excitation. The multiply 
labeled monovalent ligands were tetramerized via their bind-
ing to streptavidin, which increased probe brightness fourfold 
(FIG. la). MTRIPs, when delivered via reversible cell mem-
brane permeabilization with streptolysin 0 (FIG. lb), 
allowed for single RNA molecule sensitivity using conven-
tional fluorescence microscopy techniques. The target RNA 
was identified by the enhanced signal-to-background ratio 
10 
achieved through the binding of multiple MTRIPs per RNA 
(two or three), via Watson-Crick base pairing, or if using a 
single MTRIP per RNA, through the natural localization of 
RNA (FIG. le). This is analogous to the MS2-GFP binding 
15 systems, but uses native target sequences and fewer binding To assess the effects of streptolysin 0, and the Invitrogen 
L-3224 Live/Dead Viability/Cytotoxicity kit for mammalian 
cells was used as per the manufacturer's instructions. The 
images were taken on a Zeiss 200M widefield epifluores-
cence microscope with an LD Plan-Neofluar x20, NA=0.4 
objective, Hamamatsu ORCA ER-AG camera, and appropri- 20 
ate filter sets. 
sites. 
To characterize probe sensitivity and delivery to the cyto-
sol, probes targeting the genomic RNA of the wild-type strain 
A2 of human respiratory syncytial virus (hRSV) were immo-
bilized on glass surfaces and delivered them into non-infected 
A549 cells using streptolysin 0. More specifically, probes at 
EXPERIMENTAL RESULTS 
Currently researchers use a vast excess of probes or plas-
mid-derived RNA to image RNA with single-molecule sen-
sitivity. Either both the RNA and probe are expressed from a 
plasmid, requiring binding of up to 48 MS2-GFP molecules, 
or just the RNA is expressed from a plasmid, requiring bind-
ing sites for 96 molecular beacon probes to achieve single-
molecule sensitivity. As plasmid-derived RNA restricts usage 
to cell types that can be efficiently transfected and is suscep-
tible to artifacts caused by overexpression, imaging native 
RNA is preferred, but requires a more sensitive probe to 
achieve single-molecule sensitivity with a limited number of 
bound probes. Multiply labeled tetravalent RNA imaging 
probes (MTRIPs) were designed composed of a 2'-0-methyl 
RNA-DNA chimera nucleic acid ligand with four or five 
amino-modified thymidines, 5' biotin modification and a 
short (5-7-base) poly(T) sequence to extend the ligands from 
the surface of streptavidin. The amino-modified thymidines 
were used to conjugate N-hydroxysuccinimide (NHS) ester-
modified fluorophores to the ligand. On average, each ligand 
was labeled with three fluorophores, limiting self-quenching. 
2 nM concentrations were immobilized on a glass surface by 
adding them in growth media to a coverslip well and incubat-
ing them for 10 minutes at 3 7° C. The mixture was removed, 
25 growth medium was added, and the glass surface was imaged. 
Individual batches of each probe (see FIG. 4a), in addition to 
a mixture ofCy3B andATTO 647N labeled probes (see inset 
image FIG. 4a), were imaged on the glass surface. Individual 
probes were identified, and the mean intensity within the 
30 diffraction limited spots was plotted as a histogram (FIG. 4b ). 
After examining the images of the probe mixtures on glass, 
the histograms of mean probe intensity and three-dimen-
sional plots of the intensity of individual probes on the glass 
surface, we concluded that the images detected single probes 
35 and not aggregates (Table 1 and FIG. 4). If the probes were 
aggregating, the histograms would show non-unimodal 
behavior and mixtures of different color probes would co-
localize, which was not the case. In addition, hRSV targeting 
probes labeled with Cy3B (GE Healthcare) and Atta 647N 
40 (Atta-Tee GmbH) were delivered into non-infected A549 
cells. From a single optical plane within the live cell, indi-
vidual probes were observed as being homogenously distrib-
uted in the cytoplasm (FIG. ld-e) and localization or accu-
mulation of probes was not observed. 
TABLE 1 
SEQ ID 
NO RNA Target Ligand 
Accession 
Number & 
Location within 
Gene 
SEQ ID hRSV 5'-biotin-UXTXTTXAAAAAXGGGGCAAAXAA-3' M74568; 39-55; 
590-606; 2323-
2339 
NO 2 genomic 
RNA 
Human 
13-actin 
mRNA 
SEQ ID Probe 1 
NO 3 
SEQ ID Probe 2 
NO 4 
Chicken 
13-actin 
mRNA 
NM_OOllOl. 2 
5'-biotin-UXTTTXAXAGCACAGCCXGGAXA-3' 494-478 
5'-biotin-TTTTTTXAUUXCCCGCXCGGCCGXG-3' 696-679 
US 8,785,615 B2 
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Ligand 
TABLE 1-continued 
Accession 
Number & 
Location within 
Gene 
20 
SEQ ID Probe 1 
NO 5 
5'-biotin-TTTTTXGGAGXAACGCGGXCAGXCAG-3' 57-38 (61-38 
Tyagi, 2004) 
SEQ ID Probe 2 
NO 6 
5'-biotin-TTXTTTCAAXAUCAXCAUCCAXGGC-3' 84-66 (83-66 
Tyagi, 2004) 
SEQ ID Probe 3 5' -biotin-TTTTTXAGGAXACCXCUUXUGCUCXGG-3' 262-242 (262-240 
NO 7 Tyagi, 2004) 
Chicken arp2 NM_205224 
mRNA 
SEQ ID Probe 1 5'-biotin-TTTTXTTUCCXCCCCAGCGXGUCCA-3' 130-112 
NO 8 
SEQ ID Probe 2 5'-biotin-TTTTTXACCAAGCXTCXCCAGCACAC-3' 1280-1261 
NO 9 
SEQ ID Probe 3 5'-biotin-TTTXTTCAGXUGAXCUTAXAAUAGG-3' 243-225 
NO 10 
SEQ ID Scrambled 5'-biotin-TTTTTTTXCUAAXACXGUAXCAUCXGC-3' 
NO 11 Probe 
Boldface: 2'-0-Methyl RNA; X: dt C6-NH2; all others are DNA; 
underline: hybridization region 
To test the ability to image single RNAs, two Cy3B-labeled 30 
MTRIPs designed to target two regions of the human ~-actin 
mRNA coding sequence (human ~-actin mRNA probes 1 and 
2; Table 1) and anAtto 647N-labeled 'scrambled' probe (no 
target in human genome) (30 nM each) were simultaneously 
delivered using streptolysin 0 into A549 cells. Twenty min- 35 
utes after delivery, the cells were fixed in 4% paraformalde-
hyde and subsequently imaged. Individual RNAs could be 
imaged in both fixed and live cells, but the cells were fixed for 
quantification because of the dynamic nature of RNA gran-
ules. For ~-actin, individual 'unbound' probes were observed 40 
as well as localized granules with twice the intensity (FIG. 
2a-c ). ~-actin mRNA was prevalent in the perinuclear region 
of the cell and also localized to the leading edges, whereas the 
'scrambled' probe produced perinuclear signals and localized 
not at the cell periphery but in the cytoplasm, demonstrating 45 
~-actin probe specificity. Localization was quantified in an 
intensity profile of the confocal image (FIG. 2b ). From the 
lower-noise, widefield-deconvolved image (FIG. 2c), the 
average single-probe intensities, quantified from probes on 
the glass surface, were removed via thresholding, and the 50 
remaining granules were counted using Volocity (Improvi-
sion) software. Using this approach, single ~-actin mRNAs, 
containing approximately twice the single probe intensity, 
were observed in the cell (FIG. 2c) and a total of 1,455 
granules was detected. Granule mean fluorescence intensity 55 
(calculated from the three-dimensional reconstruction) had a 
measured s.d. of only 25% of the mean, reflecting the unifor-
mity of the granules when measured in three dimensions. The 
granule count was consistent with previous quantifications 
(1,500 in serum-stimulated cells), using a similar analysis for 60 
~-actin mRNA in epithelial cells. In addition, ~-actin mRNA 
granules were imaged in living cells by time-lapse widefield 
fluorescence microscopy (FIG. 2d). Images were collected 
with 90-ms exposure times at both 1 Hz and 5 Hz for 3 min 
and 30 s, respectively. This demonstrated the capacity to use 65 
this method in low and high-speed tracking experiments; 
similar particle trajectories have been demonstrated for plas-
mid-derived mRNAs. As an additional control, A549 cells 
were serum starved for 48 h, and the ~-actin mRNA granules 
in cells fixed after live-cell hybridization were counted. A 
representative cell contained only 409 granules as compared 
with 1,455 granules detected in a cell grown with serum (data 
not shown), consistent with previous experiments. We also 
performed single-probe imaging of clustered RNAs and co-
localized them with ~-actin mRNA binding protein, ZBPl in 
three dimensions (FIGS. 5 and 6), and simultaneously imaged 
~-actin mRNA, actin-related protein 2 homolog mRNA and 
ZBPl protein, in primary chicken embryonic fibroblasts 
(FIG. 7). 
Further evidence that these probes can be used to image 
native RNA was provided by targeting human ~-actin mRNA 
in motile A549 cells. In this case, when targeting ~-actin 
mRNA only one site, previously identified, was used (see 
Table 1 ). ~-actin mRNA, in motile cells, has been described to 
colocalize with the RNA binding protein, ZBP12 and with 
F-actin. Delivering MTRIPs at 30 nM and 1 nM concentra-
tions, those associations were easily observed in cells fixed 
post live-cell hybridization and stained with an anti-ZBPl 
antibody. In FIG. Sa-b outstretched pseudopods showed co lo-
calization in both the image and in the intensity profile plot, 
while in FIG. Sc-d, MTRIPs were observed aligned with 
stained stress fibers (see merge as well as inset image). From 
the widefield deconvolved 2D images, 3D images were 
reconstructed in Improvision's Volocity software (FIG. 6a). 
From the overlap of voxels generated in Volocity, the 
Manders overlap coefficient was calculated as 0.92, (FIG. 6b) 
clearly indicating colocalization in three dimensions between 
human ~-actin mRNA detected with MTRIPs and ZBPl. 
In order to show the flexibility and applicability of this 
method, simultaneous imaging of two mRNAs in primary 
chicken embryonic fibroblasts (CEF) was performed (FIG. 
7). CEFs were used because they have been a well-studied 
model system for studying RNA localization. Three MTRIPS 
targeting separate sequences on ~-actin mRNA and arp2 
mRNA were chosen based on both previous sequences used 4 
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and mFOLD folding of arp2 mRNA, where large single 
stranded loop sections were chosen. Even though only 2 
probes per RNA are necessary for specific detection in non-
clustered RNA (see FIG. 2), in order to optimize the signal for 
future dynamics studies, three probes per RNA were utilized 5 
(Table 1). ~-actin targeted MTRIPs were labeled withATTO 
64 7N and arp2 targeted pro bes with Cy3 B. Pro bes were deliv-
ered into CEFs (30 nM for each probe) for 10 minutes via 
SLO permeabilization; twenty minutes after delivery one set 
of cells was fixed for ZBPl immunostaining while the other 10 
set utilized for live-cell imaging. In FIG. 7a an extended view 
image of arp2 (red) and ~-actin (blue) mRNA, and ZBPl 
(green) in a motile primary CEF is presented. Intensity pro-
files (FIG. 7a-b) through two cross-sections of the extended 
view demonstrate two types oflocalization; in the perinuclear 15 
region, ~-actin mRNA signal is not correlated with the arp2 
mRNA signal, especially from approximately pixel 100 to 
225 in profile 1 and from 100 to 150 and 17 5 to 225 in profile 
2; ZBPl and ~-actin mRNA are correlated within these same 
regions. While, from a single plane image (FIG. 7c-j) of the 20 
cell near the glass surface, (FIG. 7c-d); co localization of arp2 
(red) and ~-actin (blue) mRNA, and ZBPl (green) can be 
observed within the lamellipodium, especially at the leading 
edge. Similar colocalization of the RNAs was observed in the 
live-cell image within a cellular protrusion and along the 25 
cellular periphery; this was demonstrated quantitatively in the 
intensity profiles (FIG. 7g-h ). In addition, in order to demon-
strate that SLO delivery does not significantly affect even 
primary cells, phase contrast images of representative cells 
before and after SLO exposure (FIG. 7i), show no changes in 30 
cell morphology or their ability to create lamellipodia, nec-
essary for motility. 
The localization of both mRNA within the lamellipodia 
shown here, is consistent with a previous report on their 
localization; our data though suggests that the two mRNA are 35 
likely separate within the perinuclear region but are packaged 
together when transported to protrusions or lamellipodia. 
This is reasonable given a report that arp3 mRNA likely 
contain a ZBPl binding site, and from our own sequence 
aligrnnents (data not shown), arp2 mRNA are also likely to 40 
contain one. From the one previous report5, they claim these 
mRNA localize but do not colocalize, but from our examina-
tion of their data (data not shown), they may have underesti-
mated the amount of colocalization. 
To test the utility of these probes for the study of RNA- 45 
protein colocalization in live cells, Cy3B-labeled MTRIPs 
targeted to the genomic RNA ofhRSV were used in conjunc-
tion with a GFP-TIA-1 fusion protein in infectedA549 cells, 
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confirm the probes were binding to functional, biologically 
relevant populations of RNA. Intensity profiles, as well as 
merged images from a single image plane, are displayed to 
show RNA-protein co localization. A single probe was used to 
target the gene-end-intergenic-gene-start sequence of the 
hRSV genome, which has 3 exact repeats 7 (see Table 1). 
When delivered at 30 nM concentrations, localized signal was 
observed within 10 minutes. Following fixation and staining, 
the RNA signal was observed to be colocalized (yellow) with 
the nucleocapsid (N) protein, in the infectedA549 cells. This 
colocalization was observed in the merged image as well as in 
an intensity profile intersecting granules (FIG. Sa-b ), while in 
the non-infected cells, only background signal was evident 
(FIG. Sc-d). The hRSV N protein was chosen because it is 
known to associate strongly with hRSV viral genomic RNA. 
This experiment was repeated and followed by 3D imaging 
with a laser scanning confocal microscope; 2D images were 
reconstructed in 3D in Improvision's Volocity software (FIG. 
9). From the overlap of voxels generated in Volocity, the 
Manders overlap coefficient was calculated as 0.65, clearly 
indicating colocalization in three dimensions between the 
viral RNA detected with MTRIPs and the nucleocapsid pro-
tein. 
Tetravalent MTRIPs and monovalent probes (single mul-
tiply-labeled ligand) both targeted to hRSV genomic RNA 
were delivered via SLO, each at 30 nM, into separate wells of 
A549 cells, each infected from the exact same vial of virus, 24 
hrs post-infection. The cells were then fixed in 4% paraform-
aldehyde and imaged via laser scarming confocal. From the 
reconstructed 3D images of the cells (see extended view 
images of the cells in FIG. lOa), the number of viral RNA 
granules could be counted for each probe type. It should be 
noted that even though the number of granules detected is 
statistically similar via the Wilcoxon-Mann-Whitney test, the 
photomultiplier voltage on the laser scanning confocal micro-
scope was approximately 4 times higher for the monovalent 
probe, which was expected. By combining 4 ligands, the 
resulting MTRIPs were 4 times brighter, a necessity for the 
live-cell imaging in FIG. 3. From the results of counting RNA 
granules from over 30 cells (FIG. lOb) for both the tetravalent 
and monovalent probes, the statistical similarity of the two 
populations could be estimated using the Wilcoxon-Marm-
Whitney test. From this test, the resulting p value of0.87 was 
determined, which conclusively demonstrates that the 
samples originated from the same population. This conclu-
sively shows that MTRIPs do not significantly aggregate 
RNA; RNA aggregation would have resulted in the detection 
of different numbers of RNA granules. 
To induce stress granules, the cells were exposed to 1.0 
mM sodium arsenite and substantial transient interactions 
were observed between stress and viral RNA granules (FIG. 
3b-d). A stress granule was observed moving into a viral RNA 
granule and residing within it for over a minute before it was 
released (FIG. 3c). Another stress granule then appeared to 
dock with a viral RNA granule (FIG. 3d), and appeared to be 
in contact for approximately 45 s. Transient interactions 
between RNA granules on the same time scales had been 
reported, supporting our observations, but previously engi-
neered RNAs or proteins were imaged, in contrast to the 
to evaluate the interaction between the stress granule protein 
TIA-1 and hRSV viral RNA when stress granules were 50 
induced by sodium arsenite treatment. Previous findings 
demonstrated that paramyxovirus RNA, which contains 
many possible TIA-1 or TIAR binding sites (uracil-rich 
regions), likely interacts with stress granules; this interaction 
though, has not been characterized in living cells. In hRSV- 55 
infected cells transfected with GFP-TIA-1, stress granules 
had not formed 24 h after infection as identified by the lack of 
aggregation ofGFP-TIA-1 in cells also containing viral RNA 
(FIG. 3a). MTRIPs were specific and did not aggregate RNA 
(FIGS. 8-10). 
More specifically, in order to show that these probes can 
target viral RNA molecules specifically within living cells, 
MTRIPs targeted to the genomic RNA ofhRSV and ~-actin 
mRNA were assembled, delivered via SLO into infected and 
non-infected cells, fixed in paraformaldehyde post-hybrid- 65 
ization and stained for known RNA binding proteins or co lo-
calized molecules. This experiment was performed in order to 
60 non-engineered RNAs imaged in this study. More stable 
interactions were observed between GFP-TIA-1 and the viral 
RNA (FIGS. 11 and 12). 
In addition to the transient behavior shown in FIG. 3, 
GFP-TIA-1 was also notably visible on some of the viral 
RNA granules approximately 20 to 30 minutes after sodium 
arsenite treatment. Their association was confirmed by cap-
turing video images of RNA granules during both a fusion 
US 8,785,615 B2 
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(FIG. 11) and splitting event (FIG. 12), and observing the 
protein follow the same dynamic course as the RNA. The 
overlap is not perfect, suggesting that only some of the RNA 
in the granule may be in contact with GFP-TIA-1, but the 
association is quite obvious. This finding suggests that there 5 
may be multiple mechanisms by which TIA-1 interacts with 
RNA, in a transient, granule-granule manner (FIG. 3), which 
may depend on granule size, and also through a more stable 
event, driven by RNA-protein binding. 
In this Example, we demonstrated that MTRIPs have 10 
single-molecule sensitivity and can be used to target and 
follow native and nonengineered RNA granules in living 
cells, in both a cell line and a primary fibroblast using strep-
tolysin 0 delivery; streptolysin 0 delivery induced only mini-
mal cell death (FIG. 13) and did not change cellular morphol- 15 
ogy appreciably or induce stress granules. Owing to their 
brightness at multiple wavelengths, small size and ease of 
assembly, these probes should be broadly applicable for 
studying single-molecule RNA-related events in living cells. 
24 
fluorophores that can be added to a single probe. Streptavidin 
also contributes significantly to the molecular weight of the 
pro be (-53 kDa) and might affect the delivery pathway during 
cell penetrating peptide-mediated delivery. In this Example, 
we report the synthesis and application of a multivalent RNA 
imaging probe that utilizes an eight-armed poly( ethylene gly-
col) (PEG) core. These probes overcome the main limitations 
imposed by streptavidin by increasing the number of bound 
ligands while reducing the molecular weight of the core (20 
kDa). Moreover, the probes are stabilized by employing a 
covalent bond between the ligand and the core. PEG was 
chosen, since it has been shown to reduce toxicity, reduce 
nonspecific binding, and improve internalization when con-
jugated to macromolecules and utilized in vivo. 
In order to demonstrate the efficiency of probe delivery and 
targeting, we utilized the genomic viral RNA (vRNA) of 
human respiratory syncytial virus (hRSV) as a model system. 
The localization of the vRNA ofhRSV has been previously 
characterized by both molecular beacons and MTRIPs and 
showed high concentrations of viral RNA in cytoplasmic foci 
termed inclusion bodies. Delivery of probe into live cells was 
achieved using reversible membrane permeabilization with 
streptolysin 0 (SLO), which has been shown to allow for 
efficient and homogeneous delivery of macromolecules into 
the cytoplasm. The use ofSLO results in-100% probe deliv-
ery efficiency and results in minimal cytotoxicity. Alterna-
tively, as a delivery strategy, we also used the cell penetrating 
peptide (CCP) TAT, which, when conjugated to macromol-
ecules, has been shown to transduce them across the plasma 
membrane. Indeed, the use of the PEG core permits an 
increase in the number of bound ligands and allows for the 
conjugation of delivery and targeting peptides along with 
To this end, a standard live/dead viability/cytotoxicity assay 20 
(Invitrogen L-3224) was performed to assess the effect of 
SLO on A549 cells (FIG. 13). The assay was performed on 
normally growing cells and cells exposed to 0.2 U/ml of 
activated SLO for 10 minutes. From the results in FIG. 13, it 
can be seen that SLO exposure does not change cell morphol- 25 
ogy and is associated with minimal cell death (green cells are 
living while red cells are dead). From statistics generated 
from over 700 cells in each group, 98.85 percent of the cells 
that were not exposed to SLO were alive, while 96.85 percent 
were alive after SLO exposure. SLO was associated with only 30 
a two percent increase in cell death over the normally growing 
cells. This is consistent with a previous live/dead assay per-
formed on Hela cells reported by Paillasson et al. (1997). 
They reported 95% alive in normally growing cells, and 93% 
alive when exposed to SL08. 35 RNA targeting oligonucleotides, while maintaining single 
molecule sensitivity. CPP-conjugated probes are currently of 
great interest in molecular imaging since they have the advan-
tage of being suitable for use in vivo when labeled with 
near-infrared fluorophores. As with SLO, CPP based delivery 
Example 2 
Single Molecule Sensitive Multivalent Polyethylene 
Glycol Probes for RNA Imaging 
The below Example was published inBioconjugate Chem-
istry, Vol. 21. No. 3 (February 2010). Consequently the ref-
erenced Figures can be viewed in color in this publication, 
which is hereby incorporated by reference. 
40 allows for -100% delivery efficiency and low cytotoxicity at 
low concentrations and eliminates the need forpermeabiliza-
tion of the membrane, reducing the complexity of the experi-
mental procedure. 
45 
Materials and Methods. 
Multivalent PEG Probes. 
2'-0-Me RNA/DNA chimeric oligonucleotides were syn-
thesized by Biosearch Technologies, Inc. (Novato, Calif.) 
with the following sequence, (SEQ ID NO 12) 5'-UXTXT-
TXAAAAAXGGGGCAAAXAA-3', where the boldface 
type is 2'-0-Methyl RNA, the Xis a dT-C6-NH2, the 5'-U 
contains a free thiol group, and all others are DNA. The 
binding region is underlined. 
Single molecule imaging of native and nonengineered 
RNAs in live cells has recently been achieved by the use of 
multiply labeled tetravalent RNA imaging probes (MTRIPs ). 
These probes consist of four fluorescently labeled linear oli-
gonucleotides bound together by a biotin-streptavidin linkage 50 
and recognize their intracellular target RNA through Watson-
Crick base pairing. Signal is raised above background by the 
binding of 2-3 probes per target RNA and through the natural 
localization of the target RNA. Prior to the introduction of 
MTRIPs, single molecule studies of specific RNA localiza-
tion and transport in live cells were limited to plasmid derived 
RNAs either containing binding site repeats for the MS2-GFP 
fusion protein or containing binding site repeats for a molecu-
55 Structure of the internal amine modified thymidines 
lar beacon. Plasmid derived RNAs offer tremendous method-
ological flexibility, but they preclude the study of native RNA 60 
or nonengineered viral RNA and do not allow for imaging 
native RNAs in vivo. 
While MTRIPs have proven to be capable of targeting a 
number ofRNAs in various cell types with single RNA sen-
sitivity, the use of a streptavidin core imparts some limita- 65 
tions. Pro bes with a streptavidin core have a maximum of four 
noncovalently bound ligands, which limits the number of 
0 0 
HN~N~NH2 
5'i, J-__J H 
oi;r-o2-f-J 
kr--fk 
0 H 
I O=P-o-
1 
o"l.3' 
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-continued 
Structure of the 5' thiol modified 2'-0-Methyl Uridine 
Probes were synthesized by first labeling the individual 
ligands with amine reactive NHS ester fluorophores Atta 488 
(ATTO-TEC GmbH), Cy3B (GE Healthcare), or Atta 647N 
(ATTO-TEC GmbH) using the manufacturer's protocols. 
Ligands were subsequently linked to 20 kDa eight-armed 
maleimide poly( ethylene glycol) (8-Arm PEG) cores (NOF 
America) by incubation in a 64:1 molar ratio in PBS (Am-
bion) and 1 mM EDTA (Ambion) for 12 hat room tempera-
ture. 8-Armed PEG probes with TAT were synthesized by 
adding ligand, Cys-TAT (Anaspec, Cys-TAT 4 7-57), and 
8-Arm-PEG cores in a 64:8:1 molar ratio in lOxPBS, and 1 
mM EDTA for 12 h at room temperature. All probes were 
filtered to remove free ligand and reaction buffer using 30 
kDa molecular weight cutoff Nanosep centrifugal devices 
(Pall Corp.). Purified probes were resuspended in nuclease 
free PBS and stored at 4 ° C. 
Structure of the 8-Ann maleimide activated PEG 
Cells and Virus. 
A549 human lung carcinoma cells (ATCC CCL-185) were 
cultured in DMEM (Lonza) with 10% FBS (Hyclone), 100 
U/mL penicillin, and 100 U/mL streptomycin (Invitrogen). 
Cells were plated on glass coverslips one day prior to experi-
ments. The A2 strain of human respiratory syncytial virus 
(hRSV) (Crowe laboratory, Vanderbilt University) was used 
at a MOI) 1 and a titer of lx106 TCID50 mL-1. 
Probe Delivery. 
26 
(-Ca2 + -Mg2 +) (Thermo) and then incubated with delivery 
medium containing 0.2 U/mL SLO and 5 nM probe in PBS 
(-Ca2 +-Mg2 ±) for 10 mM at 37° C. The delivery medium 
was then removed and replaced with complete growth media 
5 for 15 min. For TAT mediated delivery of probes, infected and 
noninfected cells were incubated in complete medium con-
taining 5 nMTATconjugated probe for 10mMat37° C., after 
which it was replaced with complete medium for 15 mM For 
live cell imaging experiments, growth media was replaced 
10 
with Leibovitz' s L15 medium (Invitrogen) immediately prior 
to image acquisition. 
Immunostaining. 
After probe delivery, cells were rinsed in PBS (Ambion), 
fixed with 4% paraformaldehyde (Electron Microscopy Sci-
15 ence) in PBS, permeabilized using 0.2% Triton-X 100 
(Sigma), and blocked with 5% bovine serum albumin (Am-
bion). Cells were then incubated with a mouse monoclonal 
primary antibody against the hRSV NViral Protein (Abeam), 
CD63 (Developmental Studies Hybridoma Bank), or 
20 LAMP-1 (Developmental Studies Hybridoma Bank) for 30 
mM at 37° C. and with a goat anti-mouse secondary antibody 
labeled with Alexa 488 (Invitrogen) for 30 min at 37° C. After 
DAPI staining (Invitrogen), cells were mounted on slides 
using PVA with DABCO (Sigma). 
25 Fluorescence Imaging. 
Samples were imaged using a Zeiss Axiovert 200 M epif-
luorescent microscope with a 63x=l .4 NA Plan-Apochromat 
objective, using Chroma 49002 ET-GFP (FITC/Cy2), 49004 
ET Cy3, 49006 ET Cy5 filter sets, an EXPO excite 120 for 
fluorescence excitation, a Polytek PI objective piezo for tak-
ing stacks of images, and a Hamamatsu ORCAER AG for 
55 capturing digital images. Image z-stacks were acquired in 200 
nm steps using Volocity (Improvision). Exposure times for 
probes on glass (FIG. 15) were approximately 500 ms. Expo-
sure times for probes in endosomal and lysosomal marker 
colocalization studies were 400 ms for noninfected cells 
60 (FIG. 16c-d) and 30 ms for infected cells (FIG. 16e:f). Expo-
sure times for RSV vRNA in infected cells and controls, both 
fixed and live, were approximately 100 ms (FIGS. 17-18). 
Identical exposure times in FIGS. 17 and 18 were used for 
Probes were delivered into A549 cells using reversible 
membrane permeabilization and peptide mediated delivery. 
For reversible membrane permeabilization, 2 U/mL Streptol-
ysin 0 (SLO) (Sigma) were first reduced using 7.5 mM Tris 65 
(2-carboxyethyl)phosphine (TCEP) (Peirce) for 1 hat 37° C. 
Infected and noninfected cells were rinsed using PBS 
comparison of intensities. 
Image Analysis. 
All images were deconvolved using the iterative restora-
tion algorithm in Volocity. Histograms of mean fluorescence 
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intensity were generated by identifying objects with mini-
mum and maximum intensities set to 4 SD and I 00 SD, 
respectively. Objects smaller than I point spread function 
were removed. Intensity Profiles were generated using 
Image) (NIH) Color Profiler plug-in and data tables were 5 
imported into Sigma Plot I I (Systat Software Inc.) for plot-
ting. Manders overlap coefficient was calculated using Voloc-
ity software. 
Determination of the Degree of Labeling. 
The degree oflabeling (DOL) of the oligonucleotides, i.e. 10 
the average number of dyes per oligonucleotide, was deter-
mined by measuring the UV-VIS spectrum of the conjugate 
solution in a quartz cuvette in order to obtain the absorbance 
at the absorption maximum of the dye and at 260 nm. The 
concentrations of the oligonucleotides and the dyes were 15 
calculated using the Lambert-Beer law and the extinction 
coefficients provided by the manufacturers (FIG. 19a). The 
average number of labeled oligonucleotides per activated 
PEG was estimated by measuring the conjugate absorbance at 
the absorption maximum of the dye and dividing it by the 20 
previously determined DOL (FIG. l9b ). The same procedure 
was used to determine the average number of labeled oligo-
nucleotides conjugated to the PEG-TAT probes (FIG. 19c ). 
The average number of TAT peptides per PEG molecule was 
determined by absorption spectroscopy after conjugation to 25 
PEG of unlabeled oligonucleotides and fluorescein-labeled 
Cys-TAT (Cys-TAT-FAM, Anaspec) (FIG. 19d). 
In order to validate our estimation of probe concentrations 
and ensure that unconjugated oligonucleotides were 
adequately removed upon filtration, gel electrophoresis was 30 
performed (FIG. 20) using I5% TBE-UREA gels according 
to manufacturer's protocols (Invitrogen). Analysis showed 
that less than I 0% of the unbound oligonucleotides contribute 
to the absorption spectroscopy measurements after filtration. 
Unfortunately, gel electrophoresis did not prove to be useful 35 
to investigate the homogeneity of the conjugates, due to the 
lack of clear bands. However, analysis of the microscopy data 
28 
state excitation. The use ofligands with a 2'-0-Methyl back-
bone conferred increased affinity for the target mRNA, 
increased signal-to-noise ratio, and nuclease resistance. 
In order to test the ligands for nonspecific aggregation, the 
probes were labeled with Atta 488, Cy3B, or Atta 647N 
fluorophores and were adsorbed onto a cover glass at I nM 
concentration.Using wide-field fluorescence microscopy, the 
probes were visible as distinct spots on the glass without 
apparent aggregation (FIG. 15a). Lack of aggregation was 
confirmed both by fluorescence intensity histograms (FIG. 
lSb-d) and by the lack of colocalization of probes labeled 
with different fluorophores. When the probes were delivered 
at 5 nM to include all the relevant signal within the three-
dimensional cell. The uniformity of the signal within the 
cytoplasm indicated that probe was not aggregating due to 
nonspecific interaction with cellular components. 
Recent reports have shown that macromolecule uptake by 
TAT can proceed through an endocytic pathway, even if this 
has been suggested to be dependent upon the conjugated 
macromolecule. Nonendosomal transduction of the probes is 
recommended, since it reduces the exposure of the probe to 
nucleases and eliminates the need for endosomal releasing 
agents such as poly(propylacrylic acid) to be added to the 
delivery medium. In order to determine whether or not TAT 
conjugated probes entered cells through the endosomal path-
way, TAT-probes were delivered at 5 nM into uninfected and 
hRSV infected cells that were subsequently fixed and immu-
nostained for endosomal and lysosomal markers. Cells were 
immunostained for cluster of differentiation 63 (CD63) (FIG. 
16c, e) and lysosomal associated membrane protein I 
(LAMPI) (FIG. l6dj). Multicolor images were obtained by 
wide-field fluorescence microscopy and deconvolution, and 
revealed little colocalized signal between the TAT-conjugated 
probe and protein markers. In these figures, extended views 
were shown to illustrate the signal within the cell. Some 
apparent colocalization may be perceived using this presen-
tation due to the merging of signal from different z-planes. 
Inset images from one z-plane were included to show the lack 
of colocalization qualitatively. This was confirmed quantita-
in FIG. 2 showed that the mean fluorescence intensity of 
single probes had a measured standard deviation of about 5% 
of the mean. 
Results and Discussion 
hRSV specific ligands were composed of 2'-0-Methyl-
RNA and DNA chimeric oligonucleotides with five amine-
modified thymidines and a 5' thiol modification. The oligo-
nucleotide sequence was designed to be complementary to a 
gene-end-intergenic-gene-start sequence ofhRSV which has 
three exact repeats in the hRSV genome and is not present in 
the human genome. The sequence used has previously been 
shown to be accessible by antisense knockdown experiments, 
molecular beacon imaging, and MTRIP imaging. The target-
ing of three repeats per RNA raises signal significantly above 
background for even a single RNA per point spread function. 
40 tively by low Manders overlap coefficients (R<O.I) for the 
colocalization of the probe with CD63 and with LAMPI 
using three-dimensional reconstructions of the images. 
In order to demonstrate the applicability of these pro bes for 
live cell imaging, the viral genomic RNA of hRSV was 
45 imaged in A549 cells both live and after fixation and immu-
nostaining of the hRSV N protein. The hRSV N protein has 
been shown to reside within inclusion bodies, to colocalize 
with the hRSV genome in imaging experiments, and to bind 
to hRSV vRNA. Co-localization with the N protein served to 
50 demonstrate the accurate targeting of the probe to the vRNA. 
The amine-modified thymidines of the ligands were used 
to conjugate NHS-ester fluorophores, and the thiol group was 
used to link the individual ligands to the PEG cores, which 55 
were functionalized with eight maleimide active groups (FIG. 
14a). Absorption spectroscopy showed that, on average, 3 
dyes were conjugated to each ligand and 6.5 ligands were 
conjugated to each PEG core. Probes utilizing the TAT CPP 
contained an average of 4 oligonucleotides ligands and I TAT 60 
peptide. By increasing the brightness of the probes through 
the use of multiple ligands, rather than increasing the number 
of fluorophores per ligand, self-quenching was minimized 
and ligand size was kept to approximately 20 bases. The 
fluorophores (Atta 488, Cy3B, and Atta 647N) were chosen 65 
for their strong absorption in visible wavelengths commonly 
used for imaging, high quantum efficiency, and low triplet 
A549 cells were infected with the A2 strain of hRSV and 
incubated for 24 h. Probes were then delivered at 5 nM via 
SLO membrane permeabilization and allowed to recover. 
Subsequently, cells were either fixed with 4% paraformalde-
hyde for immunostaining or stained with Hoechst 33342 for 
live cell imaging. Cells fixed and immunostained for the 
hRSV N protein showed vRNA localization near the plasma 
membrane and exhibited co localization with hRSV N protein 
similar to previously reported data (FIG. 17 a). In order to 
quantify the degree of colocalization between the vRNA and 
N protein, Manders overlap coefficients were generated using 
voxel intensities. Overlap coefficients were generally high, 
typically R>0.8. FIG. 17a shows a representative cell with an 
overlap coefficient of 0.843. In addition to whole cell auto-
matic colocalization, intensity profiles showed correlation 
between the hRSV genomic and N protein signal (FIG. 17c, 
d). In the live cell images, similar localization of the vRNA 
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was observed with vRNA predominantly residing in inclu-
sion bodies close to the cell membrane (FIG. 17e). Delivery 
of probe into noninfected cells served as a negative control 
and resulted in little to no signal when imaged under the same 
conditions as the infected cells (FIG. l 7b,j). Interestingly, 
probes delivered into noninfected cells demonstrated no sig-
nificant nuclear background. 
30 
We subsequently delivered the TAT conjugated probes at 5 
nM concentration into hRSV infected and noninfectedA549 
cells. These probes revealed a similar pattern of RNA local-
ization as the SLO-delivered ones in infected cells both live 
and upon fixation. In the latter case, colocalization with the 
viral N protein at the plasma membrane confirmed efficient 
vRNA targeting (FIG. lSa,c,d). In noninfected cells, TAT-
conjugated probes exhibited little to no signal (FIG. lSb) and 15 
appeared to be homogeneously distributed in the cytoplasm 
(FIG. 16b). While the mechanism for TAT-mediated probe 
delivery is not yet fully understood, our data strongly suggest 
that it does not involve an endosomal pathway and are con-
sistent with previous reports. In particular, Vives et al. 20 
reported that fluorescently labeled TAT peptides were effi-
ciently taken up by cells within 5 min at concentrations as low 
lation of mRNAs and for the late stages of the viral life cycle 
such as replication and packaging of viral genomic RNA. The 
RNA molecule, along with trans-acting factors, ultimately 
determines the function of the RNA. In vitro methods for 
studying these ribonucleoprotein complexes (RNPs) give 
only an averaged view of the function of these complexes. 
However, within the cellular context, these RNPs are often 
heterogeneous, and as such, methods are needed that enable 
the study of the spatial and temporal dynamics of RNA and 
10 interaction with RNA binding proteins within the cell. These 
methods must be sensitive because of the low concentration 
of specific RNAs inside the cell, and must be able to provide 
accurate subcellular localization of RNA. 
as 100 nM, and the internalization process was shown not to 
involve an endocytic pathway. The sensitivity of the fluores-
cein reporter precluded measurements using TAT concentra- 25 
tions below 100 nM. In our case, uptake of probes occurred in 
less than 10 min at a concentration of 5 nM. Moreover, our 
probes showed no colocalization with endosomal and lyso-
somal markers, and colocalized well with the N protein, 
yielding a distribution similar to the one observed in SLO 30 
membrane permeabilization-based delivery. Additionally, 
live cell imaging experiments confirmed the results and indi-
cated that cell fixation does not later probe localization. 
Using an eight-arm activated PEG core as a multifunc-
tional platform, we have developed a single molecule sensi-
tive RNA imaging probe. Fluorescently labeled oligonucle-
otides bound to the PEG core were delivered into live cells 
using two delivery methods, reversible membrane permeabi-
lization and TAT-mediated transduction. Individual probes 
were visible both on glass and inside the cells using widefield 
fluorescence microscopy. TAT-mediated delivery did not 
result in accumulation of probes in endosomes, nor did it 
result in the nonspecific aggregation of probes inside the cell. 
To demonstrate the accurate targeting of RNA in the cell, 
probes targeted against RSV vRNA were delivered into 
infected cells and demonstrated subcellular localization at the 
plasma membrane, co localization with known vRNA binding 
proteins, and signal substantially higher than in mock 
infected controls. Signal was observed in less than 10 min 
regardless of the delivery method and in the presence of probe 
concentrations of 5 nM. The rapid binding of the probes to 
their target is an essential feature for the study of RNA 
dynamics, because it allows for the observation of phenom-
CONCLUSION 
The importance of trans-acting factors, such as RNA bind-
ing proteins and noncoding RNAs, in the regulation of mRNA 
and viral RNAs has recently garnered increased attention. 
These factors are responsible for the post-translational regu-
35 ena that occur on short time scales. In addition to this, the low 
concentration of the probes contributes to reduce nonspecific 
binding. Our results suggest that TAT (or other CPPs) conju-
gated PEG probes may allow for the imaging of specific 
RNAs in vivo when combined with fluorophores that absorb 
in the near-infrared wavelengths. 
<160> NUMBER OF SEQ ID NOS, 12 
<210> SEQ ID NO 1 
<211> LENGTH, 15 
<212> TYPE, PRT 
SEQUENCE LISTING 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic peptide 
<400> SEQUENCE, 1 
Cys Gly Pro Glu Asn Gly Arg Arg Gly Gly Phe Gly Ser Arg Gly 
1 5 10 15 
<210> SEQ ID NO 2 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, nucleic acid probe 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1) .. (1) 
<223> OTHER INFORMATION, 5'-biotin-labeled residue 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
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<222> LOCATION, (1) .. (1) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (2) .. (2) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (2) .. (2) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (4) .. (4) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (4) .. (4) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (7) .. (7) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (7) .. (7) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (8) .. (12) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (13) .. (13) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (13) .. (13) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (14) .. (21) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (22) .. (22) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (22) .. (22) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (23) .. (24) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<400> SEQUENCE, 2 
untnttnaaa aanggggcaa anaa 
<210> SEQ ID NO 3 
<211> LENGTH, 23 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, nucleic acid probe 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (1) .. (1) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1) .. (1) 
-continued 
<223> OTHER INFORMATION, 5'-biotin-labeled residue 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (2) .. (2) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
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<221> NAME/KEY, misc_feature 
<222> LOCATION, (2) .. (2) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (6) .. (6) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (6) .. (6) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (7) .. (7) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (8) .. (8) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (8) .. (8) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (9) .. (17) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (18) .. (18) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (18) .. (18) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (19) .. (21) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (22) .. (22) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (22) .. (22) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (23) .. (23) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<400> SEQUENCE, 3 
untttnanag cacagccngg ana 
<210> SEQ ID NO 4 
<211> LENGTH, 25 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, nucleic acid probe 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1) .. (1) 
-continued 
<223> OTHER INFORMATION, 5'-biotin-labeled residue 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (7) .. (7) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (7) .. (7) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (8) .. (10) 
<223> OTHER INFORMATION, 2'-0-Methyl 
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<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (11) .. (11) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (11) .. (11) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (12) .. (16) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (17) .. (17) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (17) .. (17) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (18) .. (23) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (24) .. (24) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (24) .. (24) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (25) .. (25) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<400> SEQUENCE, 4 
ttttttnauu ncccgcncgg ccgng 
<210> SEQ ID NO 5 
<211> LENGTH, 26 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, nucleic acid probe 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1) .. (1) 
-continued 
<223> OTHER INFORMATION, 5'-biotin-labeled residue 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (6) .. (6) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (6) .. (6) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (7) .. (10) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (11) .. (11) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (11) .. (11) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (12) .. (18) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (19) .. (19) 
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<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (19) .. (19) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (20) .. (22) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (23) .. (23) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (23) .. (23) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (24) .. (26) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<400> SEQUENCE, 5 
tttttnggag naacgcggnc agncag 
<210> SEQ ID NO 6 
<211> LENGTH, 25 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, nucleic acid probe 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1) .. (1) 
-continued 
<223> OTHER INFORMATION, 5'-biotin-labeled residue 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (3) .. (3) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (3) .. (3) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (7) .. (9) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (10) .. (10) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (10) .. (10) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (11) .. (14) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (15) .. (15) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (15) .. (15) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (16) .. (21) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (22) .. (22) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
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<222> LOCATION, (22) .. (22) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (23) .. (25) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<400> SEQUENCE, 
ttntttcaan aucancaucc anggc 
<210> SEQ ID NO 7 
<211> LENGTH, 27 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, nucleic acid probe 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1) .. (1) 
-continued 
<223> OTHER INFORMATION, 5'-biotin-labeled residue 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (6) .. (6) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (6) .. (6) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (7) .. (10) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (11) .. (11) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (11) .. (11) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (12) .. (14) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (15) .. (15) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (15) .. (15) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (16) .. (18) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (19) .. (19) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (19) .. (19) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (20) .. (24) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (25) .. (25) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (25) .. (25) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
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<221> NAME/KEY, modified_base 
<222> LOCATION, (26) .. (27) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<400> SEQUENCE, 7 
tttttnagga naccncuuna gcucngg 
<210> SEQ ID NO 8 
<211> LENGTH, 25 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, nucleic acid probe 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1) .. (1) 
-continued 
<223> OTHER INFORMATION, 5'-biotin-labeled residue 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (5) .. (5) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (5) .. (5) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (8) .. (10) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (11) .. (11) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (11) .. (11) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (12) .. (19) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (20) .. (20) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (20) .. (20) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (21) .. (25) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<400> SEQUENCE, 8 
ttttnttucc nccccagcgn gucca 
<210> SEQ ID NO 9 
<211> LENGTH, 26 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, nucleic acid probe 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1) .. (1) 
<223> OTHER INFORMATION, 5'-biotin-labeled residue 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (6) .. (6) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (6) .. (6) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
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<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (7) .. (13) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (14) .. (14) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (14) .. (14) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (16) .. (16) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (17) .. (17) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (17) .. (17) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (18) .. (25) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<400> SEQUENCE, 9 
tttttnacca agcntcncca gcacac 
<210> SEQ ID NO 10 
<211> LENGTH, 25 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, nucleic acid probe 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1) .. (1) 
-continued 
<223> OTHER INFORMATION, 5'-biotin-labeled residue 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (4) .. (4) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (4) .. (4) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (7) .. (9) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (10) .. (10) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (10) .. (10) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (11) .. (13) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (14) .. (14) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (14) .. (14) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (15) .. (16) 
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<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (18) .. (25) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (19) .. (19) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (19) .. (19) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<400> SEQUENCE, 10 
tttnttcagn ugancutana auagg 
<210> SEQ ID NO 11 
<211> LENGTH, 27 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, nucleic acid probe 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1) .. (1) 
-continued 
<223> OTHER INFORMATION, 5'-biotin-labeled residue 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (8) .. (8) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (8) .. (8) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (9) .. (12) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (13) .. (13) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (13) .. (13) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (14) .. (15) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (16) .. (16) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (17) .. (19) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (20) .. (20) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (20) .. (20) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (21) .. (24) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (25) .. (25) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
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<222> LOCATION, (25) .. (25) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (26) .. (27) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<400> SEQUENCE, 11 
tttttttncu aanacuguan caucngc 
<210> SEQ ID NO 12 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, nucleic acid probe 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (1) .. (1) 
-continued 
<223> OTHER INFORMATION, 5'-biotin-labeled residue 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (1) .. (1) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (2) .. (2) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (2) .. (2) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (4) .. (4) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (4) .. (4) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (7) .. (7) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (8) .. (12) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (13) .. (13) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (13) .. (13) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (14) .. (21) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (22) .. (22) 
<223> OTHER INFORMATION, dT-C6-NH2 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (22) .. (22) 
<223> OTHER INFORMATION, n is a, c, g, t or u 
<220> FEATURE, 
<221> NAME/KEY, modified_base 
<222> LOCATION, (23) .. (24) 
<223> OTHER INFORMATION, 2'-0-Methyl 
<400> SEQUENCE, 12 
untnttnaaa aanggggcaa anaa 
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What is claimed is: 
1. A biomolecule probe comprising: 
a multivalent core comprising a plurality of attaclnnent 
sites; 
a plurality of RNA/DNA chimeric linear oligonucleotides 
having specificity for a target, wherein the plurality of 
RNA/DNA chimeric linear oligonucleotides are each 
bound to an attaclnnent site of the multivalent core; and 
a plurality of reporter molecules, wherein each reporter 
molecule is bound to the RNA/DNA chimeric linear 
oligonucleotide. 
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16. The RNA imaging probe of claim 13, wherein the 
RNA/DNA chimeric linear oligonucleotide comprises an 
attaclnnent region, a spacer region, and a hybridization 
region. 
17. The RNA imaging probe of claim 16, wherein multi-
valent core comprises a tetravalent strepavidin core, and 
wherein the attaclnnent region of the RNA/DNA chimeric 
linear oligonucleotide comprises biotin. 
18. The RNA imaging probe of claim 16, wherein multi-
10 valent core comprises a multivalent polyethylene glycol core, 
and wherein the attaclnnent group comprises a 5' thiol modi-
fied 2'-0-methyl uridine. 
2. The biomolecule probe of claim 1, wherein a ratio of the 
plurality of RNA/DNA chimeric linear oligonucleotides to 
the plurality of attaclnnent sites on the multivalent core is 15 
equal to or less than about 1. 
19. The RNA imaging probe of claim 16, wherein the 
spacer region comprises a plurality of deoxythymidines, a 
plurality of deoxyadenonsines, or combinations thereof. 
20. The RNA imaging probe of claim 16, wherein the 
RNA/DNA chimeric linear oligonucleotide further com-
prises a plurality of amino-modified deoxythymidines. 3. The biomolecule probe of claim 1, wherein a ratio of 
reporter molecule to plurality of RNA/DNA chimeric linear 
oligonucleotides is greater than or equal to about 1. 
21. The RNA imaging probe of claim 13 further compris-
ing a targeting moiety. 
4. The biomolecule probe of claim 3, wherein the ratio of 20 
reporter molecule to the plurality of RNA/DNA chimeric 
linear oligonucleotides is about 3. 
22. The RNA imaging probe of claim 13 further compris-
ing an epitope moiety. 
23. A method for detecting a single molecule of RNA using 
the RNA imaging probe of claim 13 comprising: 5. The biomolecule probe of claim 4, wherein the target is 
a RNA. delivering an effective amount of the RNA imaging probe 
to a cell; and 
detecting a molecule of a target RNA in a cell. 6. The biomolecule probe of claim 4, wherein the reporter 25 
molecule comprises a fluorophore. 24. The method for detecting a single molecule of RNA of 
claim 23, wherein the effective amount of an RNA imaging 
probe has a concentration of less than about 1 micromolar 
30 (µM). 
7. The biomolecule probe of claim 3, wherein the nucleic 
acid comprises an attaclnnent region, a spacer region, and a 
hybridization region. 
8. The biomolecule probe of claim 3, wherein multivalent 
core comprises avidin or a derivative thereof. 
9. The biomolecule probe of claim 3, wherein multivalent 
core comprises a multivalent polyethylene glycol core. 
10. The biomolecule probe of claim 9, further comprising 
a peptide, wherein the peptide is bound to an attaclnnent site 
of the multivalent polyethylene glycol core. 
11. The biomolecule probe of claim 10, wherein the pep-
tide comprises a targeting moiety. 
12. The biomolecule probe of claim 10, wherein the pep-
tide comprises an epitope moiety. 
13. A RNA imaging probe comprising: 
a multivalent core comprising a plurality of attaclnnent 
sites; 
a plurality of RNA/DNA chimeric linear oligonucleotides 
having a specificity for a plurality of sites on a target 
RNA, wherein a RNA/DNA chimeric linear oligonucle-
otide is bound to an attaclnnent site of the multivalent 
core; and 
a plurality of fluorophores, wherein a fluorophore is bound 
to the RNA/DNA chimeric linear oligonucleotide. 
14. The RNA imaging probe of claim 13, wherein a ratio of 
fluorophore to RNA/DNA chimeric linear oligonucleotide is 
greater than 1. 
15. The RNA imaging probe of claim 14, wherein a ratio of 
fluorophore to RNA/DNA chimeric linear oligonucleotide is 
greater than or equal to about 3. 
25. The method for detecting a single molecule of RNA of 
claim 24, wherein the effective amount of an effective amount 
of an RNA imaging probe has a concentration ranging from 
about 5 nanomolar (nM) to about 30 nanomolar (nM). 
26. The method for detecting a single molecule of RNA of 
35 claim 23, wherein the delivering an effective amount of an 
RNA imaging probe to a cell comprises permeabilizing the 
cell with streptolysin 0. 
27. The method for detecting a single molecule of RNA of 
claim 23, wherein the delivering an effective amount of an 
40 RNA imaging probe to a cell comprises microinjecting the 
RNA imaging probe into a cell. 
28. The method for detecting a single molecule of RNA of 
claim 23, wherein the detecting a molecule of a RNA in a cell 
comprises visualizing the association of the RNA imaging 
45 probe with the molecule of a target RNA in a cell through 
microscopy. 
29. The method for detecting a single molecule of RNA of 
claim 23, wherein the RNA is a native, non-engineered RNA. 
30. The method for detecting a single molecule of RNA of 
50 claim 23, wherein the RNA is a cellular RNA. 
31. The method for detecting a single molecule of RNA of 
claim 30, further comprising detecting a protein that is asso-
ciated with the target RNA. 
32. The method for detecting a single molecule of RNA of 
55 claim 23, wherein the RNA is a viral RNA. 
* * * * * 
